Abstract: Current treatment modalities for musculoskeletal injuries due to disease or trauma often implement the use of tissue grafts, cell transplantations, and artificial scaffolding. These approaches may be augmented with the use of specific biological factors, which accelerate healthy tissue regeneration. Unfortunately, the short half-life and inherent instability of proteins requires the delivery of high doses or multiple doses of these molecules, neither of which is ideal for the patient or clinician. Gene therapy, as an alternative approach, has the potential to circumvent the existing limitations associated with protein delivery by producing a sustained release of the biologic agent at therapeutic levels. This is achieved by the direct transfer of the gene encoding the therapeutic agent to the cells of the afflicted tissue or by implanting cells that have been previously genetically modified in vitro. Using these methods, several laboratories have demonstrated the ability to deliver genes in vitro and in vivo resulting in accelerated and enhanced musculoskeletal tissue regeneration or inhibited disease progression. Many of these investigations, which involved bone, ligament, tendon, and cartilage, are covered in this review. Specifically, musculoskeletal tissue anatomy, factors relevant to musculoskeletal tissue regeneration, target cells, and in vivo and ex vivo gene therapy approaches for musculoskeletal regeneration are discussed. The experience and knowledge gained from these studies have affirmed gene therapy is a promising therapeutic strategy to combat musculoskeletal tissue repair and regeneration following disease or injury.
INTRODUCTION
Musculoskeletal disorders are a major health concern worldwide. In the United States, more than 200,000 bone grafting procedures [Stevenson 1999 ] and more than 500,000 cartilage repair procedures are performed per year [Laurencin et al. 1999; Mason et al. 2000] . During the period from 1990-1995, there was an average of 54,000 hospital admissions for repair of the anterior cruciate ligament [Laurencin et al. 1999] . In vitro and in vivo investigations have established that accelerated healing of the musculoskeletal tissues, including bone, cartilage, ligament, and tendon, can be achieved by the continued application of appropriate and specific cytokines and growth factors. Traditional approaches to cytokine delivery; however, are often unsuccessful. The oral administration of proteins is ineffective as the molecules are metabolically liable. The potential loss of activity during storage, the characteristic short half-life, and the inability of growth factors to selectively target tissues require high concentrations of the protein to be used in either systemic or local delivery strategies. Such high doses may be detrimental if delivered to non-target organs or if unexpected dose dumping occurs. For example, the systemic delivery of TGF-β has been shown to be immunosuppressive and promote tissue fibrosis of the kidney. Localized factor delivery systems have been designed for implantation at the target site. The incorporated proteins; however, are susceptible to *Address correspondence to this Suite 330, 400 Ray C. Hunt Drive, Charlottesville, VA 22903, USA; Tel: 434-243-0250; Fax: 434-243-0252; Email: CTL3F@Virginia.edu denaturation and resultant inactivity from the processing techniques used to combine the bioactive factor with its carrier. Furthermore, several studies have demonstrated microgram quantities of biologically active molecules are often needed to elicit a healing response where often picogram to nanogram levels are naturally expressed. This large discrepancy further illustrates the difficulties encountered in designing efficient and reliable protein delivery systems.
The use of transfected cells expressing these molecules offers an alternative strategy to the delivery of recombinant protein. Transfection may be achieved via gene delivery to the target cell using an in vivo or ex vivo strategy. An in vivo gene therapy approach involves the direct implantation or injection of a vector encoding for the therapeutic gene and thereby genetic modification of the target cells in the patient. An ex vivo gene therapy approach involves harvesting the target cells, expanding the quantity of cells using cell culture techniques, transfecting the cells in vitro, and implanting the genetically modified cells in the patient. Both approaches lead to transfected cells synthesizing the therapeutic agent at the selected site.
Several advantages exist in employing gene therapy over traditional protein delivery systems. Theoretically, high dosages are unnecessary as the protein is produced locally in a continuous manner using natural cellular mechanisms. Targeted growth factor delivery may be achieved following a single treatment, which is attractive for both the patient and clinician. Concurrently, it is often difficult to target specific cells using an in vivo gene therapy approach and to correlate in vitro or in vivo transfection efficiencies to dosages between independent investigators. Questions also exist as to whether sufficient healing may occur before gene expression via a transient transfection will cease (~7-14 days).
In time, we will know a therapeutic dosage range for the local and regional gene delivery of each biologic agent. Currently, questions remain concerning appropriate dosages. In general, below the therapeutic dose, no significant beneficial response can be measured. At dosages within the therapeutic range, a significant therapeutic effect may be measured as compared to untreated controls. Above the therapeutic dose, a humoral or cellular response may be observed. In a severe response, a systemic immune reaction resulting in morbundity or death may occur. For this reason, dosages in gene therapy strategies are of utmost importance; however, differences between independent research investigations make comparisons difficult.
The use of gene therapy strategies to treat the majority of musculoskeletal diseases and traumas are in its infancy as the optimal gene products, transfer vector, route of administration, and expression levels have yet to be determined. Meanwhile, great advances have been made in the use of gene therapy to treat musculoskeletal disorders, such as a torn ligaments, and diseases, such as rheumatoid arthritis. This review discusses the use of gene therapy in the regeneration of the musculoskeletal tissues: bone, ligament, tendon, and cartilage. Each section covers basic tissue anatomy and function, the growth factors and cytokines that stimulate tissue development and regeneration, appropriate target cells for transfection, and the gene therapy strategies under investigation to enhance musculoskeletal tissue regeneration or to prevent disease progression. The experience and knowledge gained from these investigations have affirmed the belief that gene therapy is a promising therapeutic strategy for musculoskeletal tissue repair and regeneration following disease or injury.
BONE

Anatomy and Function
Bones comprise the majority of the skeleton in most vertebrates. Physically, bone functions to support the body, act as a lever system during movement, and protect internal organs. Its physiological functions include hematopoiesis, the formation of blood cells, and mineral homeostasis, as a reservoir for calcium, phosphorus, sodium, potassium, zinc and magnesium. The inorganic mineral hydroxyapatite (Ca10(PO4)6(OH)2) comprises 67% of bone, while the remaining 33% is organic matrix, consisting of 25% type I collagen and 5% noncollagenous protein, including osteocalcin, bone sialoprotein, bone growth factors, and bone proteoglycan. As bone is continuously synthesized and resorbed, bone forming cells at different stages of maturation may be found. These cells include the osteoblast progenitors, osteoblasts, osteocytes, and bone lining cells. Osteoclasts are the cells responsible for the degradation of bone.
Cortical bone is the dense external layer comprising the walls of diaphyses and external surfaces of bone. The central medullary cavity of compact bone is filled with bone marrow. Throughout the length of the marrow cavity exists a reticular network of trabecular bone, whose primary function is to reinforce the outer cortical bone. Haversian systems are the structural units that comprise cortical bone. Each system consists of a concentric lamella of inorganic matrix, the osteon, with a central Haversian canal. Volkmann canals connect adjacent Haversian canals. Blood vessels and nerves pass through the canals and govern the nutrient supply to osteoblasts. The concentric lamella and accompanying structures are surrounded by the circumferential lamellae, which forms the outer perimeter of cortical bone. The two most outer tissue layers comprise the periosteum. The inner layer consists of osteoblasts and osteoprogenitor cells and a vascular supply, while the outer fibrous layer gives rise to Sharpey fibers, which extend into the circumferential lamellae.
Regulatory Factors in Bone Development and Regeneration
Several growth factors, including insulin-like growth factors I and II (IGF-I and -II), transforming growth factor-β (TGF-β), platelet derived growth factor (PDGF), acidic and basic fibroblast growth factors (aFGF and bFGF) and the bone morphogenetic proteins (BMPs), have been shown to contribute to bone development and regeneration processes. These molecules act through autocrine and paracrine signaling mechanisms to induce the migration, proliferation, and differentiation of osteoprogenitor cells and/or type I collagen synthesis and matrix apposition by mature osteoblasts. During bone formation, IGF-I, IGF-II, TGF-β, aFGF, bFGF and BMPs are stored in the extracellular matrix. Upon matrix destruction, either through natural bone remodeling processes or bone fracture, these factors are released to initiate osseous healing and maintain the cyclic anabolic and catabolic processes that continually remodel bone.
PDGF is the single factor listed here that is not produced by osteoblasts, but it is locally released at an osseous site by platelets, macrophages, monocytes, and endothelial cells [Khan et al. 2000] . This factor has been shown to increase DNA synthesis and cell proliferation. PDGF has also been shown to stimulate interleukin-6 (IL-6) production by osteoblasts, which enhances the recruitment of osteoclasts.
IGF-I and -II play a significant role in skeletal development by promoting cell proliferation and matrix synthesis by osteoblasts. IGF-II is the most abundant growth factor stored in human bone matrix and the full extent of the contribution by IGFs to osseous remodeling and bone repair remains unclear. Although IGFs induce cell proliferation, increase type I collagen synthesis and promote the differentiation of osteoblast precursors, IGFs also stimulate osteoclast formation and thereby may increase bone resorption. Many studies have shown a stimulatory effect on bone formation whereas other studies have shown no such response [Khan et al. 2000] .
The FGFs influence the activity of undifferentiated stem cells and differentiated osteoblasts. They induce osteoprogenitor cell migration, proliferation, and differentiation. Endothelial cells respond to FGF stimulation by migration, proliferation, and angiogenesis [Ludwig et al. 1999] . The factor is a mitogen for fibroblasts, osteoblasts, and chondrocytes. However, high dosages of FGFs have been shown to decrease alkaline phosphatase levels, type I collagen formation and mineralization, thereby inhibiting cartilage and bone formation.
TGF-β is initially released into an osseous defect site by platelets contributing to hematoma formation and later by the chondrocytes and osteoblasts contributing to new bone formation. This factor has been demonstrated to increase cell proliferation, angiogenesis, collagenous and non-collagenous protein production. In vivo studies have demonstrated the increased biomechanical strength of healed fractures treated with TGF-β as compared to controls, which healed with no exogenous TGF-β applied. It acts as a morphogen at the bone defect site by inducing endochondral bone formation [Rosier et al. 1998 ]; however, the osteoinductive effect of TGF-β is weaker than the BMPs as it cannot initiate the osteoinduction cascade and form ectopic bone by itself as several BMPs can [Ludwig et al. 1999] .
BMPs are a family of proteins, related to TGF-β, capable of inducing orthotopic and heterotopic bone formation. The potency of recombinant adenoviruses expressing fourteen human BMPs (BMP-2 to BMP-15) to transfect and differentiate osteoblastic progenitor cells was recently investigated [Cheng et al. 2003 ]. In vitro results indicated BMP-2, -6, and -9 contributed to the osteogenic differentiation of mesenchymal stem cells. An independent study, which compared the in vitro and in vivo osteogenic induction, by BMP-2, -4, -6, -7, and -9 following adenoviral transfection, also demonstrated the potency of BMP-6 and BMP-9 ]. In general, the BMP osteogenic response is both dose and species dependent. Other investigations have indicated BMP-2, -4, -5 and -7 demonstrate the greatest mitogenic response without osteoclast stimulation, which is occasionally observed during the use of IGFs and TGF-βs [Linkhart et al. 1996] . With the exception of the non-osteogenic BMP-1, the BMPs act as chemoattractants for human osteoblasts, induce the differentiation of osteoblast precursor cells into mature osteoblasts, and induce endochondral bone formation [Baltzer et al. 1999; Krebsbach et al. 2000; Ludwig et al. 1999] . BMP-2 has also been shown to inhibit the terminal differentiation of myoblasts and adipocytes and induce the differentiation of muscle-derived and adipose tissue-derived stem cells along an osteoblast lineage [Dragoo et al. 2003; Lee et al. 2000; Lee et al. 2001; Lee et al. 2002; . The intramuscular injection of BMP-9 producing human mesenchymal stem cells induced ectopic bone formation in athymic nude rats [Dayoub et al. 2003 ]. These cells were found to contribute to ectopic bone formation and recruit host stem cells, that also contributed to osteogenesis. Computerized tomography scans of the injected thighs indicated bone formation became evident at three weeks post-injection. By day 42 post-injection, an organized bone matrix and mature bone tissue occupied the injection site. In this model, ex vivo gene therapy demonstrated BMP-9 to be a potent inductor of ectopic bone formation.
This limited list comprises potential growth factors for gene therapy strategies designed to augment bone formation. Although most experimental approaches are focused on the delivery of genes promoting the overexpression of bone growth factors, the gene encoding the osteoblast-specific transcriptional activators Runx2/Cbfa1 and LIM mineralization protein-1 (LMP-1) have also been explored. A transcription factor acts within the nucleus of a cell to promote the expression of a specific gene or group of genes. Unlike the aforementioned growth factors, which are secreted proteins that bind to a cell surface receptor to initiate a response, the transcription factor is an intracellular signaling molecule that must be synthesized inside the cell to exert its osteoinductive effect. Therefore, any attempt at the in vivo use of a transcription factor requires the techniques of gene therapy to deliver the cDNA inside the cell to result in the synthesis of the transcription factor in situ.
The overexpression of Runx2, delivered to osteoblastlike and non-osteoblastic cells using retroviral gene delivery, resulted in sustained expression of the transcriptional activator and the overexpression of specific osteogenic markers in both cell types. The non-osteoblastic fibroblast cells did express osteocalcin, but did not express bone sialoprotein (BSP) or alkaline phosphatase (AP) [Byers et al. 2002] . The lack of BSP and AP expression was believed to further account for the lack of in vitro mineralization by the fibroblast cells. The osteoblast-like cells underwent in vitro osteoblastic differentiation and mineralization as evidenced by the expression of BSP and the formation of mineralized nodules [Byers et al. 2002 ].
An ex vivo, regional gene therapy approach delivered the transcription factor LMP-1 to achieve spinal fusion in rats [Boden et al. 1998 ]. Transfection was achieved by first incorporating the LMP-1 cDNA into a plasmid with a CMV promoter and delivering the gene to isolated bone marrow stromal cells using a commercially available lipofection kit. A negative-control plasmid containing the same DNA but in a reverse sequence was also tested. Although less than 1% of the cells were transfected, the implantation of LMP-1-transfected bone marrow cells produced posterior spinal fusion in nine of nine spines, where as no fusion was noted in the nine implants containing cells with the reversed DNA [Boden et al. 1998 ]. More recently, human lung carcinoma A549 cells were used to clearly establish which osteogenic growth factors are expressed following LMP-1 transfection . Results indicated elevated levels of BMP-2, -4, and -7 and to a lesser extent BMP-6 and TGFβ-1.
Following implantation of LMP-1 transfected human buffy-coat cells infected with LMP-1 and seeded onto a collagen sponge in athymic rats, positive staining for BMP-4 and -7 was observed at days 3-5 and again after day 10. The first peak was attributed to BMP manufactured by the transfected cells and the second peak to host osteoblast-like cells surrounding the matrix ]. These findings demonstrate the advantage of delivering a gene encoding LMP-1 over the delivery of a gene encoding a growth factor, that the expression of a single transcription factor will promote the expression of several BMPs. Thus, lower transfection efficiency or shorter duration of transgene expression may promote accelerated bone regeneration as compared to the delivery of a single gene for an osteogenic growth factor.
Studies using a more challenging immunocompetent rabbit intratransverse fusion model were also conducted [Cha et al. 2003 ]. Bone marrow derived buffy coat cells were transfected ex vivo using adenovirus encoding either LMP-1 or β-galactosidase as a control. Transfected cells were seeded on a devitalized bone matrix carrier or a collagen sponge carrier and implanted in a single-level posterior lumbar intratransverse fusion. MicroCT, radiographic, and histological analysis, at 5 weeks postoperative, indicated solid spinal fusions occurred for all implants seeded with LMP-1 expressing cells, while no bone formed where implants seeded with β-galactosidase expressing cells were used.
A collagen-ceramic composite scaffold was then used to provide additional stability at the implantation site. Radiographic analysis indicated all ten implants seeded with LMP-1 expressing buffy coat cells had a denser appearance. The presence of ceramic interfered with detection of new bone formation in histological and radiographical analysis. The control implants, seeded with cells transfected with empty virus, displayed no evidence of bone formation. These studies demonstrate local gene therapy using buffy coat cells transfected ex vivo using adenovirus encoding LMP-1 is effective in promoting spinal fusion in immune competent animals. These findings further emphasize that successful spinal fusion may be achieved with low levels of transfected cells. As adenoviral vectors and cells previously transfected using adenovirus may evoke an immune response, the advantage of this strategy is that immune system detection and a subsequent immune response, which would hinder new bone formation at the implant site, may be avoided.
Cells for Gene Therapy Strategies Directed Towards Bone Regeneration
In the human skeleton, bone growth is accomplished by osteoblasts, which are terminally differentiated, nonproliferating cells that reside in bone matrix. Bone marrow stromal cells are often selected for use in bone regeneration strategies as this heterogeneous cell population contains osteoprogenitor (mesenchymal stem) cells that may differentiate into mature osteoblasts. Several investigators believe the use of a homogenous cell population is unnecessary because as the factors are locally produced; bone healing is accelerated regardless of the cell type secreting the growth factor. To heal a bone defect, the need for an alternative cell source may be required if the host bone tissue is of poor quality or of insufficient quantity. Alternative cell sources for use in bone regeneration include fibroblasts, muscle-derived cells, and adipose tissue-derived cells. Fibroblasts and cells of muscle or adipocyte origin are easily biopsied, rapidly expanded in vitro, and readily transfected using viral or non-viral vectors. The latter two cell types also possess osteocompetence, so in addition to delivering the therapeutic protein, the cells may contribute to the healing response.
A cloned, pluripotential, mesenchymal cell line, termed D1, and primary rabbit bone marrow stromal cell line were examined for their ability to be transfected without adversely altering the expression of bone and cartilage phenotypic markers [Milbrandt et al. 2003] . Results indicated the D1 cells showed a 10-fold decrease in alkaline phosphatase expression following retroviral transfection as compared to non-transfected D1 cell cultures. Osteocalcin mRNA expression was 1.5-fold greater in non-transfected D1 cells at 7 days post-transfection. By day 14, the expression of osteocalcin mRNA was reduced in both transfected and nontransfected D1 cells.
Rat dermal and human gingival fibroblasts have been transfected with the BMP-7 gene for an ex vivo bone regeneration approach [Krebsbach et al. 2000] . In this study, BMP-7 transfected human gingival fibroblasts cultured on a bovine bone-collagen carrier were able to induce osteogenesis in vivo when implanted in the derma of immunocompromised mice. By two weeks, marrow containing ossicles had formed in all 30 transplants containing the BMP-7 transfected cells. The new bone was restricted to the shape of the implant with no signs of inflammation to the surrounding region. No evidence of bone formation was found in the control matrices, which consisted of fibroblasts transfected using adenovirus encoding LacZ and loaded in a gelatin carrier. Antibodies against the bone marker osteonectin distinguished human osteonectin at the center of the transplant and murine osteonectin at increased levels on the periphery of the transplant. Immunohistochemistry and in situ hybridization studies indicated the transfected fibroblasts secreted bioactive BMP-7 promoted osteogenesis by the donor fibroblasts as well as host cells. These results demonstrated the osteoinduction of host cells by the transfected nonosteogenic fibroblasts and the differentiation of donor fibroblast cells.
The potential for cells that reside in the muscle to form bone was demonstrated by the formation of ectopic bone following the implantation of demineralized bone matrix in a muscle pouch [Urist et al. 1965] . This response was attributed to bone morphogenetic protein within the demineralized bone matrix [Wang et al. 1988] . Following this, the addition of rhBMP-2 protein to C2C12 myoblast cell line culture was shown to inhibit terminal differentiation of myoblasts [Katagari et al. 1994] . RhBMP-2 growth factor inhibited the cells from fusing into multinucleated myotubes capable of spontaneous contraction and induced a response characteristic of an osteogenic lineage, including increased alkaline phosphatase and parathyroid hormone (PTH) levels and osteocalcin secretion. This work led to the application of gene therapies using muscle-derived cells for bone regeneration. Osteocompetent cells within muscle were then examined for their ability to differentiate down an osteogenic pathway following direct gene transfer. Replication deficient adenovirus particles genetically modified to express BMP-2 were directly injected into the triceps surae musculature of SCID mice and immunocompetent mice [Musgrave et al. 1999] . Radiological and histological evidence demonstrated ectopic bone formation using this direct, in vivo gene therapy approach. At all time points examined, bone formation was more pronounced in immunodeficient animals than immunocompetent animals. This was attributed to the tendency of cells transfected via adenovirus to express viral proteins and induce an immunological response, which limits transgene expression. This study established the presence of osteocompetent cells within muscle capable of osteogenic induction following gene transfer of the osteogenic protein BMP-2.
To further enhance bone formation, a clonal cell population, which possesses osteocompetence, has been isolated from the skeletal muscle tissue of the mdx mouse [Lee et al. 2000] . These cells, termed mc-13, express early myogenic markers (desmin, c-met, MNF and Bcl-2), as well as stem cell and satellite cell markers (Sca-1, Flk-1, CD34, and m-cadherin). The capacity of mc-13 cells to differentiate along osteogenic lineages in vitro and in vivo avails a homogenous cell population suitable for bone regeneration applications. The ability to isolate the osteocompetent cells allowed the use of muscle-derived cells in ex vivo gene therapy strategies to be explored. In one study, mc-13 cells were isolated, expanded in vitro, transfected using adenovirus expressing BMP-2 and implanted into SCID mouse triceps musculature [Lee et al. 2000] . The results demonstrated a sub-population of the muscle-derived cells was not only capable of delivering BMP-2, but also of contributing to the healing response. Using the same mouse model, an examination of the early fate of the BMP-2 expressing selected muscle-derived cell population identified the formation of chondrocyte lacunae, indicating endochondral ossification . No transfected cells were identified at the original implantation site; however, the possibility that the muscle-derived cells possess a chondrogenic potential and may be suitable for use in gene therapies for cartilage regeneration is under investigation [Adachi et al. 2002] . To date, findings have indicated muscle-derived cells, in collagen gels, possessed a faster proliferation rate than condrocytes under similar conditions, and both cell types demonstrated a similar pattern of healing full thickness articular cartilage defects. Thus, the advantages to using the muscle-derived cells are the ease of biopsy and rapid cell proliferation as compared to a chondrocyte harvest.
More recent work has examined the ability of musclederived stem cells (MDSCs) transfected using a retroviral vector encoding BMP-4 to promote ectopic and orthotopic bone formation in immunocompetent rats ]. Transfected MDSCs expressed high levels of active BMP-4, which inhibited myogenic and enhanced osteogenic differentiation. Thus, the transgenic cells served as osteoinductors by secreting BMP-4 and as osteoprogenitors by contributing to new bone formation. Interestingly, histological analysis indicated that BMP-4 expressing MDSCs responded to the secreted factor in an autocrine manner and underwent intramembranous bone formation by directly undergoing osteogenic differentiation and forming bone. Host osteoprogenitor cells responded to the secreted BMP-4 in a paracrine manner and underwent endochondral bone formation, whereby a cartilage intermediate, which was eventually replaced by bone, formed. Despite an immune response, indicated by the presence of CD4 and CD8 positive lymphocytes in and around the newly formed bone, the genetically modified cells produced enough BMP-4 to stimulate bone growth, indicating this approach is feasible in immune competent systems. MDSCs transfected with either the BMP-4 or VEGF transgene and implanted, at a 5:1 (BMP-4:VEGF transfected cell) ratio, demonstrated enhanced host mesenchymal stem cell recruitment and survival at the defect site . The promotion of angiogenesis by these growth factors also accelerated endochondral bone formation. In short, VEGF and BMP-4 appeared to act synergistically to enhance bone healing.
To examine the ability of efficacy of BMP-4 expressing muscle derived cells (BMP-4-MDCs) in a more clinically relevant model, a rat femoral osteotomy lesion with severe soft tissue damage was used ]. Bone fixation used a rotational, unstable K-wire or stable plate fixation. Evaluation, at six weeks post-implantation, indicated osteochondral ossification and the formation of a bridging callus at the defect site for the BMP-4-MDCs in combination with rigid plate fixation. The BMP-4-MDCs with unstable fixation showed hypertrophic chondrocytes at the defect site and a failed bridging callus at the six week time point. The detection of hypertrophic chondrocytes in the BMP-4-MDC groups at the six week time point indicated endochondral bone formation was taking more time then expected. Radiographic and histological analysis of the control experimental groups, LacZ expressing MDCs with either stable or unstable fixation, demonstrated no or limited cartilage and woven bone formed around the osteotomy at all time points examined.
In a second study, MDCs and bone marrow stromal cells (BMSCs) were genetically modified using retrovirus encoding BMP-4, seeded on a collagen sponge, and implanted in a critical-sized rat femur defect model ]. Radiographical and histological analysis of bone healing was evaluated at 4, 8, and 12 weeks post-implantation. Preliminary in vitro evaluation of the two transfected cell types examined BMP-4 release, alkaline phosphatase production, and cell proliferation. The results indicated the BMSCs secreted more BMP-4 as compared to the MDCs per 10 6 cells over 24 hours and stained positive for alkaline phosphatase. The lack of alkaline phosphatase production by the BMP-4-MDCs and rapid cellular proliferation as compared to the BMP-4-BMSCs led the investigators to conclude the BMP-4-MDCs were not osteogenic and did not directly contribute to bone formation in vivo. Healing of the femur defect was attributed to the migration and differentiation of mesenchymal stem cells from the surrounding tissues. Based on the in vitro results, the authors concluded the BMP-4-BMSCs underwent osteogenic differentiation and directly participated in new bone formation, but their limited proliferation prevented union with the host bone in 6 of the 17 samples. The pattern of endochondral bone formation and callus formation occurred in all of the bone defects treated with either BMP-4-BMSCs or BMP-4-MDCs; however, at the 12 week time point, the defect with the implanted BMP-4-MDCs demonstrated a significantly higher photodensity measurement as compared to the BMP-4-BMSC group. Control specimens, consisting of LacZ expressing MDCs seeded on a collagen sponge, failed to form cartilage or bone and the defect filled with scar tissue.
Another alternative cell source for bone regeneration is adipose tissue-derived stromal cells. Three anatomical sources for adipocytes include the bone marrow stroma, subcutaneous tissue layers, and infrapatellar fat pad. Adipose tissue, like bone marrow, derives from the embryonic mesoderm and contains a heterogeneous mix of stromal cells [Zuk et al. 2001] . Approximately 15-65% of the cells within processed liposuction aspirates (PLAs) have osteogenic potential. The PLAs require exposure to recombinant BMP or transfection with a BMP gene before these cells can initiate bone formation. In vitro studies have demonstrated PLAs to be a more desirable cell source for osseous regeneration as compared to bone marrow aspirates (BMAs) [Dragoo et al. 2002] . First, the density of stem cells in PLAs is much greater than in BMAs. Second, using an adenoviral vector, the average transduction efficiency of PLAs was 55%, while the average transduction efficiency of BMAs was 35%. Third, PLAs treated with recombinant human BMP-2 or transfected with adenovirus encoding for BMP-2 demonstrated a more rapid upregulation of markers associated with osteogenic differentiation as compared to similarly treated BMAs [Dragoo et al. 2002] . However, at later time points, both PLAs and BMAs showed evidence of differentiation into osteoblasts to the same extent, as indicated by the expression of bone sialoprotein, a bone marker only produced by mineralizing cells. An in vivo study, in which PLAs transfected via adenovirus encoding the BMP-2 gene were seeded on a type I collagen sponge and implanted into the hind limbs of SCID mice, was performed [Dragoo et al. 2002] . Histological analysis indicated abundant bone formation by the BMP producing PLAs at six weeks post-implantation. As PLAs are readily harvested, require minimal expansion, and readily form bone following transfection with a gene encoding BMP, these cells may ultimately prove to be a more desirable cell source than BMAs for use in bone regeneration therapies.
While several of these studies indicate alternative mesenchymal stem cell sources, such as muscle tissue and adipose tissue, demonstrate a greater healing efficacy or stronger osteogenic response than bone marrow stromal cells, other studies indicate osteoinduction to be independent of cell type [Gugala et al. 2003 ]. Human bone marrow mesenchymal stem cells, primary human skin fibroblasts, and a human diploid fetal lung cell line were transfected ex vivo with two distinct adenovirus vectors encoding BMP-2 and injected into the quadriceps musculature of nonobese diabetic severe combined immunodeficiency mice [Gugala et al. 2003] . No statistically significant difference was observed in the amount of ectopic bone that formed between the different cell types transfected with a chimeric adenovirus type 5 with the fiber gene of adenovirus type 35. However, smaller quantities or no bone was detected by cells originally transfected with adenovirus type 5. Thus, the authors concluded that BMP-2 expression is dependent on the adenovirus used for transfection and the resultant level of growth factor expression determines the extent of bone formation. As the transfected human cells were undetected by 7 days post-injection, the authors suggested the implanted cells delivered BMP-2, while the host cells provided the osteogenic response.
Although the optimal cell type for genetic modification with the goal of bone regeneration remains undetermined, ideal attributes of the cells are known. The cells should be easily accessible using a non-invasive procedure, available in large quantity or possess the ability for rapid expansion in vitro. Genetic modification should involve a high transfection efficiency and the transgene expressed at levels adequate to promote accelerated bone healing without inducing an adverse immunological reaction.
In Vivo Gene Therapy Strategies for Bone
The feasibility and longevity of gene expression using in vivo gene transfer to deliver transiently expressed cDNA to a bone defect was established using adenoviral particles, carrying the cDNA encoding the marker genes β-galactosidase (LacZ) and firefly luciferase, suspended in a saline solution or a collagen gel [Baltzer et al. 1999] . A 1.3 cm defect in the femoral diaphysis of rabbits was created and the muscles surrounding the defect were sutured closed to create a chamber into which the recombinant adenoviral particles were injected. The presence of the marker genes was detected in the surrounding soft tissues at 2 to 3 weeks; LacZ and luciferase expression were detected, at 6 weeks post-injection, in the local bone, bone marrow, scar tissue, callus tissue, and surrounding muscle. LacZ expression was absent from the contralateral femoral gap tissue, lung, liver and spleen; luciferase expression was absent from the contralateral femur, lung and spleen, but expressed in the liver at 5 days post-injection and not detectable at 10 days post-injection. The expression of luciferase in the liver was attributed to leakage of the viral particles during the injection procedure.
Using the same model and procedure, bone healing was stimulated when genes encoding for the osteogenic proteins BMP-2 or TGF-β were injected [Baltzer et al. 2000] . At 8 weeks, histological and radiographic analysis of segmental defects transfected using adenovirus encoding a BMP-2 gene showed complete ossification of the defect with the presence of mature bone marrow elements. Segmental defects transfected using adenovirus encoding a TGF-β gene failed to show mineralized bridging at 16 weeks by radiographic analysis, although elevated bone matrix synthesis was detected through histological analysis. It is important to note that the cells responsible for the osteogenic response observed after the delivery of adenovirus particles encoding the cDNA of BMP-2 is unknown. Due to the high transfection efficiency of the surrounding muscle cells, as measured by marker gene transfection, osteoprogenitor cells residing within the muscle are a likely candidate [Baltzer et al. 2000] . In tracking the distribution of cells transfected by adenoviral particles, it was found the muscle immediately surrounding the bone defect site contained the highest transfection levels. This was attributed to the muscle tissue being a more cellular organ as compared to the scar tissue which formed at the defect site [Baltzer et al. 1999] .
Cellular trafficking studies following systemic administration of IGF-1-producing D1 cells demonstrated the transfected cells repopulated the bone marrow and preferentially migrated to an induced femur fracture . A regional gene therapy approach was used as one million transfected cells were injected through the tail vein of Balb/c mice afflicted with a closed, transverse, midshaft femur fracture. The number of transfected cell per field in the fractured limb was statistically significant as compared to a comparable field in the contralateral limb (control) at all time points examined (2, 4, and 6 weeks). The authors did not determine why the number of transfected cells decreased over time, but this was considered a desired response as the fracture healing proceeded to eliminate long-term growth factor overexpression.
The investigation of local gene therapy for fracture repair involved the injection of thirty million murine leukemia virus-based retroviral vectors encoding a BMP-2/4 hybrid transgene or control β-galactosidase gene at the lateral side of a femoral fracture [Rundle et al. 2003 ]. Defect healing was monitored for 10 weeks. Although use of the MLV vector carried a low risk for insertational mutagenesis, it was selected primarily because it lacks the immunogenicity characteristic of other viral vectors. The MLV can only transfect dividing cells, but this feature was thought to allow the targeting of proliferating periosteal cells adjacent to the fracture site. By 7 days post-injection, a soft tissue callus surrounded the fracture site injected with vector expressing the BMP-2/4 hybrid. These sites were extensively ossified by 14 days post-injection, and by day 28, bone tissue almost bridged the fracture site. Gene therapy with the BMP-2/4 hybrid did accelerate fracture healing. Radiographs and quantitative computed tomography at 70 days posttreatment; however, indicate the fractures of both experimental and control groups had remodeled to normal dimensions with no significant difference in the area or bone mineral content of the fractures. The lack of β-galactosidase detection by polymerase chain reaction in extraskeletal tissues indicated viral transfection was limited to the proliferating cells of the fracture site. These initial studies warrant further investigations as the clinical use of in vivo gene therapy for fracture repair may be safe.
Several investigators [Bonadio 2000; Fang et al. 1996; Goldstein et al. 1999; Goldstein 2000] have successfully used an in vivo gene therapy approach to deliver plasmid DNA to musculoskeletal sites via non-viral delivery vectors. The ease of manufacture, the stability of DNA, and the absence of viral proteins, which induce immune responses, make non-viral gene transfers more economical and safer. The ability to elicit sufficient levels of transfection make in vivo non-viral delivery strategies an efficient and feasible option for the repair of musculoskeletal tissues. DNA plasmids encoding parathyroid hormone (PTH1-34) or BMP-4 or both were incorporated into collagen sponges thereby forming a gene activated matrix (GAM) [Fang et al. 1996] . Although the encoding plasmids were no longer detected by five weeks post-surgery, defects treated with genes encoding a single factor showed bony bridging at nine weeks, whereas defects treated with genes encoding both factors showed bony bridging at four weeks. The GAM was then used to heal canine femoral and tibial defects [Bonadio et al. 1999] . The DNA transfer to the target fibroblast cells within the femoral gap was found to be between 30 -50%, with continued expression up to six weeks. The activity of the transfected gene was localized at the defect site by the matrix. In a 2-cm critical sized canine tibial model, only the GAMs with the highest concentration of plasmid DNA were able to show 60-75% healing by six weeks and healing was still incomplete at twelve weeks. Further evaluation of the high DNA plasmid concentration GAMs showed that in a 1.6 cm defect one of two tibias had completely healed by eighteen weeks and four of four, 1 cm noncritical sized defects healed by eight weeks [Bonadio et al. 1999] . No biomechanical testing was performed. This approach takes advantage of the natural migration of repair fibroblasts to the defect site. On arrival at the matrix, the cells uptake the transplanted DNA and continuously deliver inductive proteins at the site of interest. The major disadvantage of this in vivo regional strategy is that it relies on the biologic potential of the host to respond to the GAM. In certain clinical situations, the bone stock may be compromised and unable to support a cell population responsive to the GAM.
Electroporation is another non-viral gene delivery approach that has been investigated as a method to promote direct in vivo bone formation. This technique uses low voltage electric pulses to create pores in the outer cell membrane, which allows intracellular entry of the delivered gene. Delivery of a BMP-4 plasmid to the gastrocnemius of mice using electric pulses, delivered through needle electrodes inserted percutaneously, demonstrated the formation of newly formed bone in 2, 4, and 2 of 6 mice at 14, 21, and 28 days post-treatment [Kishimoto et al. 2002] . Host mesenchymal stem cells infiltrated the treatment site and both endochondral and intramembraneous ossification were observed, with intramembraneous bone formation predominating. Treatment induced damage to the muscle fibers may limit the clinical application of this approach.
Ex Vivo Gene Therapy Strategies for Bone
To promote orthotopic bone formation, ex vivo regional gene therapies are the most widely investigated approach. Ex vivo strategies are preferred over in vivo as the investigator may expand the cell population prior to transfection, selectively increase the efficiency of transfection using antibiotic selection, or screen cells for tumorigenicity prior to implantation. In addition, the in vivo gene transfer strategy is dependent on the presence of responsive host cells, a limitation that is readily overcome using an ex vivo gene transfer approach.
The use of a single cell type, osteogenic factor, scaffold, and biomaterial allowed Blum et al. to directly compare the healing response due to cells transfected with one of the three vectors. Specifically, rat bone marrow stromal cells genetically modified to overexpress human BMP-2 were seeded on a titanium mesh and implanted at ectopic and orthotopic locations following transfection using an adenoviral, retroviral, or cationic lipid vector. Quantitative analysis of orthotopic bone formation in a critical-size cranial defect model indicated the bone marrow stromal cells transfected via adenovirus demonstrated significantly more bone formation in the defect than the other groups [Blum et al. 2003 ]. The genetic modification of the primary cells using the cationic lipid vector did not enhance either ectopic or orthotopic bone formation. Fluorochrome labeling indicated both transplanted and autologous cells contributed to new bone formation.
The next three studies examined the ex vivo gene transfection of bone marrow stromal cells with a gene encoding BMP-2 and the efficacy of the genetically modified cells to heal a rat femoral segmental defect. The objective of the first study was to determine whether a regional gene therapy approach could be used to heal the critical-sized, 8 mm, osseous defect. The site was filled with autologous marrow cells, previously transfected ex vivo with an adenoviral vector containing the BMP-2 gene, and mixed with guanidine extracted-demineralized bone matrix [Lieberman et al. 1999] . The limited duration of transgenic expression associated with adenoviral vectors may be advantageous in healing isolated osseous defects, as continued growth factor overexpression is unnecessary once sufficient healing has progressed. The control, demineralized bone matrix alone, demonstrated limited osteoinductive potential. Recombinant human BMP-2 was used as a positive control and bone marrow cells alone or bone marrow cells transfected with the LacZ marker gene served as negative controls. The animals were sacrificed at 2 months. Twenty-two of 24 defects treated with BMP-2 transfected bone marrow cells and all 16 defects treated with recombinant BMP-2 protein healed by radiographic criteria. Furthermore, the defects treated with the BMP-2 transfected bone marrow cells developed a dense trabecular bone with a significantly greater amount of bone per unit area. In contrast the defects treated with recombinant protein developed a thin and lacelike trabecular bone with a cortex thinner than observed in the BMP-2 producing group. Mechanical testing at eight weeks post-implantation indicated no significant difference in the energy to failure between the BMP-2-producing rat bone marrow stromal cells and intact bone; the torsional stiffness and torque to failure were lower for BMP-2-producing bone marrow cells than intact femora [Lieberman et al. 1999 ]. An assessment of BMP-2 production, by the transfected cells designated for transplantation, indicated some cell populations secreted more BMP-2 than others. BMP-2-producing bone marrow cells that secreted lower amounts of BMP-2 protein, demonstrated lower energy to failure or torque to failure than similar experimental samples. The authors speculated a threshold level of BMP-2 production may be required to heal these critical sized defects; however, a quantitative determination or speculation, as to what the BMP-2 threshold level may be, was not provided.
An independent 6mm rat femoral segmental defect corroborated these initial findings and examined whether the transfected cells served strictly for BMP delivery or also participated in bone formation [Tsuchida et al. 2003 ]. Allogenic bone marrow derived mesenchymal stem cells were transfected using adenovirus encoding BMP-2. Eight million cells were suspended in a collagen gel and implanted in the defect. These rats received a three week treatment with the immunosuppressant FK506 and were found to heal the bone defect to the same degree as autogenic MSCs genetically modified to overexpress BMP-2 with no immunosuppressant administered.
Radiographs obtained at 2, 4, 6, and 8 weeks postsurgery indicated BMP-2 expressing allogenic cells plus FK506 treatment and the BMP-2 expressing autogenic cells had a similar healing pattern. A low-density tissue filled the entire defect site and exceeded the size of the bone defect at 2 weeks post-implantation. The density of the defect site continued to increase and by 8 weeks, the defect was filled with a dense osseous tissue. At 8 weeks, six of seven femoral defects in the syngeneic BMP-2 expressing MSC group and 8 of 8 defects filled with the BMP-2 expressing allogenic MSCs plus FK506 treatment were healed. Once the immunosuppressant was discontinued, no decrease in bone formation or increased bone resorption was observed. Thus, genetically modified allogenic MSCs demonstrated the same healing response as autogenic MSCs when implantation was accompanied by short-term immunosuppressant treatment. These 2 groups yielded the same bone mineral density by 8 weeks post-implantation, but both demonstrated significantly less BMD as compared to the contralateral untreated control limb. These studies indicated the addition of the immunosuppressant was necessary, as transfected allogenic MSCs without FK506 treatment showed limited bone formation at the defect site. The immunosuppressant inhibited a host immune response, so the MSCs remained viable and unhindered in BMP-2 expression, which accelerated bone formation.
Fluorescence in situ hybridization analysis on histological sections of the newly formed bone from the allogeneic group with FK506 treatment demonstrated these cells resided in newly formed bone tissue. The authors speculated these MSCs differentiated into osteoblast cells. Thus, these cells not only deliver BMP-2, but also directly participate in the bone formation process. Control groups consisting of allogeneic or syngenic MSCs transfected with adenovirus encoding β-galactosidase, BMP-2 expressing MSCs without FK506 treatment, and an empty defect site failed to heal. Future work is directed at monitoring the longterm fate of genetically modified cells following implantation.
The third study compared adenoviral transfection to nonviral liposome mediated gene transfer ]. The two vectors were first evaluated in vitro to determine the optimal vector dose. Repeatedly, adenoviral transfection resulted in a two-fold greater number of transfected cells. Irrespective of the vector used, transfer gene expression lasted approximately 14 days. A co-culture experiment designed to determine the bioactivity of the released BMP-2 indicated both vectors induced overexpression of type I collagen mRNA and alkaline phosphatase in untreated BMSCs.
Autologous BMSC obtained from the femur of rats were modified by adenoviral or liposome-mediated BMP-2 gene transfer and implanted into a 6mm diameter defect in the mandible. Transfer gene expression was detected for two weeks in vivo. BMSCs transfected via adenovirus resulted in complete bony healing at 6 weeks post-implantation, while defects filled with BMSCs transfected using liposomes took slightly longer. Control bone defects, filled with BMSCs expressing β-galactosidase or untreated BMSCs, demonstrated only limited bone regeneration primarily at the margins of the defect after 8 weeks post-transplantation. Although BMSCs transfected with either vector resulted in trabecular bone formation, the adenovirus transfection resulted in a greater quantity of new bone formation as compared to the liposome mediated gene transfer. The authors do not mention a lack of or occurrence of an immune response, which may be induced by transplanted cells previously exposed to adenovirus. Interestingly, although the BMSCs transfected via adenovirus resulted in a slightly faster healing response and thicker bone formation, the authors concluded the non-viral liposome-mediated gene transfer was sufficient for bony healing and possibly a preferred vector system for clinical studies of gene therapy for bone regeneration. Additional reasons for their selection include the ease of preparation, ability to carry DNA of greater kilobase size, and less immunological and safety problems.
Based on the findings that ex vivo gene therapies could be used to heal segmental bone defects, investigations focused on the influence the quantity of transfected cells implanted has on osseous healing. The bone healing response by primary bone marrow stromal cells transfected ex vivo with a murine leukemia virus (MLV)-based retroviral system expressing BMP-4 demonstrated that the healing of a critical sized defect was dependent on the number of transfected cells implanted [Gysin et al. 2002] . Following implantation of the BMP-4 transfected cells in an 8 mm cranial defect using a rat model, bone formation was shown to be complete at four weeks. Specifically, 2.5 x 10 6 BMP-4 transfected bone marrow stromal cells were embedded in a gel sponge matrix and implanted into the critical size cranial defect [Gysin et al. 2002] . The use of the gel sponge matrix allowed for the implantation and localization of the transfected cells at the defect site and served as scaffolding for host progenitor cells that migrated to the defect site. Measurements of bone mineral density (BMD) indicated increased BMD from 2 to 4 weeks, with the defect area being completely filled with new bone at four weeks. Although initial bone deposition was unorganized, the bone deposited at 2 to 4 weeks was laminar in structure. The presence of osteoclasts along the outer edge of the implant at 4 weeks indicated the initiation of bone remodeling. A maximal response was observed using 1 x 10 6 transfected cells and increasing the cell number up to 5 x 10 6 did not increase or enhance the observed bone formation. The authors speculated the plateau in bone formation, despite an increase in the number of transplanted, cells may be due to a limited number of host progenitor cells available for recruitment to the defect site. The investigators also found a large discrepancy between the duration of transgene expression in vitro and in vivo. Preliminary in vitro studies demonstrated a high level of BMP-4 expression was maintained for the first 4 weeks of continuous culture, with expression levels dropping to approximately half by 8 weeks of culture. In vivo, expression decreased much faster. It was undetected by 4 weeks. Whether the loss of transgene expression was due to gene silencing, a loss of cells by migration or cell death, by immune response or lack of nutrients, is unknown at this time, but demonstrates the need for future studies to address the limiting factors that govern transgene expression and response at implantation sites.
A number of studies have combined gene therapy with a tissue engineering approach to bone regeneration. Typically, genetically modified cells are seeded on two-and threedimensional scaffolds, which are designed to support cellular attachment and proliferation. Scaffolds fabricated from the FDA approved biomaterial poly(lactide-c o-glycolide) (PLAGA) have supported cells transfected with a gene encoding for bone morphogenetic protein or the transcription factor Runx2/Cbfa1 [Byers et al. 2002; Partridge et al. 2002; Laurencin et al. 2001] .
BMP-2 transfected bone marrow stromal cells attached and proliferated on three-dimensional (3D) PLAGA scaffolds created using a gas foaming process [Partridge et al. 2002] . It was demonstrated that the released BMP-2 maintained its bioactivity by the ability of the culture supernatant to induce expression of the osteoblast phenotype by C2C12 myogenic cells. In vivo, BMP-2 transfected bone marrow stromal cells seeded on a 3D PLAGA polymeric scaffold formed mineralized tissues when placed in a diffusion chamber and implanted in nude mice [Partridge et al. 2002] , demonstrating the potential of the genetically modified cells in combination with a biodegradable polymer to form a tissue engineered construct for bone. Two-dimensional poly(lactide-co-glycolide)-hydroxyapatite (2D-PLAGA-HA) composite scaffolds supported the attachment and proliferation of BMP-2 producing W-20 cells in vitro [Laurencin et al. 2001] . Western blot analysis of the culture supernatant demonstrated continued BMP-2 production by the transfected cells cultured on the composite discs. Following in vivo implantation for one month at a heterotopic site, radiological and histological results confirmed bone formation in two out of five experimental discs [Laurencin et al. 2001] . The next step was the fabrication of a three-dimensional, porous, microsphere PLAGA-HA matrix, which supported the attachment and growth of bone marrow stromal cells transfected using adenovirus encoding BMP-2. A co-culture experiment was used to demonstrate BMP-2 transfected bone marrow stromal cells seeded on the composite scaffolds released bioactive BMP-2. These constructs promoted the differentiation of primary human mesenchymal stem cells (MSC) down an osteogenic lineage, as demonstrated by increased MSC proliferation, alkaline phosphatase expression and calcium deposition [Kofron et al. 2003 ].
Autologous bone marrow stromal cells transfected with the cDNA encoding BMP-2 using adenovirus, were mixed with collagen type I. The gel-like mix was implanted into a critical size bilateral maxillary defect, in miniature swine, with a biodegradable internal splint of polylactic acid. At three months post-implantation, histological results indicated mineralized, mature, woven bone filled the experimental defect. The control defect, consisting of β-galactosidase expressing bone marrow stromal cells mixed with type I collagen, was not healed. Mechanical testing of the BMP-2 producing cell/collagen type I matrix at three months postimplantation indicated the tissue engineered construct possessed a maximal strength in compression similar to normal maxilla bone [Chang et al. 2003 ].
Allograft tissue was used as a scaffold on which genetically modified cells were seeded to increase the rate of graft fusion and mechanical properties ]. The bone marrow cells were transfected ex vivo using adenovirus encoding BMP-7 (AdBMP-7). Transgene expression was detected for 7 days and decreased to background levels by day 14. Ten out of ten spines treated with allograft bone seeded with BMP-7 producing cells exhibited new bone formation. Radiographic analysis indicated 70% of the AdBMP-7 cells plus allograft scaffold had bilateral bridging. No new bone formation was detected in fusions that involved allograft with no cultured cells or allograft seeded with cells transfected with empty vector. Mechanical fusion was achieved in 80% of the AdBMP-7 cells plus allograft scaffold versus 0% in the control groups. The range of motion and hysteresis were lower for the AdBMP-7 cells plus allograft scaffold, which indicated spinal fusion had occurred. The failure of allograft incorporation may be caused by a host inflammatory response that initiates bone resorption. The addition of BMP-7 expressing cells appeared to counteract this response by favoring new bone formation. Future studies will further elucidate the balance bone resorption and formation rates play in osseous regeneration.
Clinical Trials for Bone Replacement
The aforementioned studies demonstrate the potential of gene therapy in bone repair and regeneration. To our knowledge, no gene therapy based clinical trials have been reported for the treatment of osseous defects or diseases.
LIGAMENT
Ligament and Tendon Anatomy
Ligaments, which connect two articulating bones across a joint, and tendons, which connect muscle to bone, consist of elastin and collagen fibres. The collagen fibrils of these tissues are arranged into fibers with a planar zig-zag or crimp structure. This morphology imparts elasticity to the tissues and allows them to be repeatedly stretched without damage to the tropocollagen molecules and fibril levels that comprise the lower hierarchical levels of these tissues. Ligaments maintain joint congruency and guide joint movement, while tendons convert muscle contractions to joint motion. Ligaments and tendons are usually injured during sport or exercise activities. The medial collateral ligament (MCL) is the most frequently torn ligament. Due to the MCLs vascularity it has a fairly good potential for self-repair, which is in contrast to the anterior cruciate ligament. This ligament has a poor healing capacity due to its avascularity and its surrounding environment of synovial fluid [Laurencin et al. 1999] .
Currently, autogenous patellar tendon with bony attachments at the ends is used to reconstruct the ACL after injury [Martinek et al. 2002] . Without the bony attachments, a fibrous tissue holding the ends of the tendon to the bone can be observed 12 months after reconstruction; when bony attachments at each end of the tendon are also transplanted, a normal insertion site is seen at approximately 6 months postoperative [Martinek et al. 2002] . Current problems with tendon reconstruction involve donor site morbidity (with use of autologous patellar tendon), rupture of the repair site and the formation of restrictive adhesions [Lou et al. 1996] . The use of gene therapy strategies to heal ligaments and tendons is in the preliminary stages and discussed below.
Ligament and Tendon Growth Factors
The main growth factors that affect the fibroblasts of ligament and tendon tissue include platelet derived growth factor-BB (PDGF-BB), epidermal growth factor (EGF), insulin-like growth factor (IGF-I) and transforming growth factor-β (TGF-β). Following tissue rupture, these growth factors are released at the wound site by local fibroblasts, platelets, and plasma to influence cell migration, proliferation, and matrix synthesis. PDGF-BB and TGF-β act individually through chemotaxis to induce cell migration [Lee et al. 1995] . PDGF has also been shown in multiple studies to increase the mechanical properties of a healing ligament [Hildebrand et al. 1998; Batten et al. 1996] , with optimal results obtained when the factor is administered soon after injury [Batten et al. 1996] . EGF, IGF-I, and PDGF-BB individually stimulate fibroblast proliferation [Schmidt et al. 1995] . IGF-I is also a chemoattractant for vascular endothelial cells and has been shown to provide an antiinflammatory action in injured Achilles tendon models [Kurtz et al. 1999] . This may act to mitigate a secondary tissue injury due to a severe inflammatory response following tissue injury. TGF-β is a stimulant of collagen and total protein synthesis, and when used in combination with EGF, improved healing of MCL was noted after injury [Hildebrand et al. 1998 ]. Bone morphogenetic proteins are traditionally known for their ability to induce bone formation at ectopic and orthotopic sites; however, BMP-12 has been shown to induce ligament and tendon formation. BMP-12 transfected pluripotent mesenchymal stem cells implanted subcutaneously and ectopically in nude mice showed the formation of a connective tissue of type I collagen fibers that surrounded a fibrocartilage tissue core [Lou et al. 2001] .
Cells for Gene Therapy Strategies Directed Towards Ligament Regeneration
Knowledge of the ability of retroviral and adenoviral vectors to infect primary ligament and tendon cell populations is important to designing efficient in vivo and ex vivo gene therapy strategies for ligament and tendon repair. The ability of these vectors to transfect anterior cruciate ligament, posterior cruciate ligament, medial collateral ligament, patellar tendon, and semitendinosus tendon cells, harvested from New Zealand White rabbits using explant culture technique, has been examined [Gerich et al. 1997] . One million particle forming units and Polybrene, to facilitate transfection, were added to 25-cm 2 tissue culture flasks at 70% confluence (retroviral) or 100% confluence (adenoviral). The results indicated all five cell types were susceptible to viral transfection; however, there was a considerable variation in vector transfection efficiency. Adenoviral transfection efficiency was 90-100% and was detected up to 7 days post-infection. Positive expression following retroviral transfection was significantly lower at 10-60%; however, retroviral transfection followed by antibiotic selection resulted in a transfection efficiency over 90% [Gerich et al. 1997] . As retroviruses are only able to transfect actively dividing cells, retroviral transfection for in vivo gene transfer to ligamentous tissue is unsuitable. It is most appropriate to use retrovirus for an ex vivo approach as significantly greater transfection efficiencies are observed when retroviral transfection is used in combination with antibiotic selection.
To demonstrate the feasibility of transfection with a clinically relevant gene, an adenoviral vector was genetically modified to deliver a BMP-12 gene to primary White Leghorn chicken tendon cells cultured in vitro [Lou et al. 2001] . Results demonstrated the transfected cells synthesized approximately 30% more type I collagen than control cultures. BMP-12 expression did not show an osteoinductive effect on these cultures, as no statistically significant difference in alkaline phosphatase expression was noted [Lou et al. 2001] .
In Vivo Gene Therapy Strategies to Intact Ligament and Tendon
An in vivo gene therapy approach to ligament and tendon healing requires a targeted transfection. Preliminary in vitro studies were first completed on semitendinuosus tendon tissue fragments, 0.5 cm in length, harvested from New Zealand White rabbits, that were untreated (control) or exposed to 3x10 9 particles of adenovirus carrying the β-galactosidase (LacZ) or firefly luciferase gene [Martinek et al. 2002] . Histological analysis indicated vector gene expression was greatest at 24 hours and gradually decreased over the next six weeks with transfected cells being limited to the superficial cell layers of the tendon fragments at all time points tested.
Local in vivo gene therapy strategies using adenovirus were conducted to determine the potential for direct gene delivery to ligament and tendon tissues. In one study, 5 x 10 6 adenovirus LacZ particles were injected into the New Zealand White rabbit patellar tendon. The contralateral patellar tendon served as the control and received an injection of 250 µl of saline [Gerich et al. 1997] . This in vivo gene transfer approach resulted in very few transfected cells within the tendon. Cell transfection was primarily surrounding vessels at the subsynovial layer near the site of injection. The accidental injection of adenovirus LacZ into the patellar tendon insertion site revealed bone cells were also transfected. No evidence of an inflammatory response was observed, and positive LacZ expression was significantly reduced by 6 weeks. In another study [Lou et al. 1996] , the direct injection of 10 5 recombinant adenovirus particles carrying the β-galactosidase gene (LacZ) into the White Leghorn chicken long toe flexor tendon and tendon sheath determined the potential for direct gene delivery to these tissues. Positive histological staining at 3, 30, and 75 days indicated transfection was limited to the epitenon cell layer of the tendon, whereas sheath staining penetrated deeper. Controls of untreated tendons and tendons with recombinant adenovirus carrying antisense cDNA were not stained by X-gal solution.
A virus dose-transfection rate study injected 3 x 10 6 , 7 x 10 6 , 1.5 x 10 7 , 3 x 10 7 , and 6 x 10 7 (particle forming units) (PFUs) into the chicken long toe flexor tendon. LacZ staining demonstrated higher virus doses resulted in greater transfection rates in the tendons. Two percent of tendon cells and 10% of sheath cells were stained at 3 x 10 6 PFU and 40% of tendon cells and 60% of sheath cells were stained at 6 x 10 7 PFU [Lou et al. 1996 ].
The findings of these studies were significant because they indicate a functional exogenous gene may be directly delivered to and continually expressed at ligament and tendon tissue. Both in vivo studies indicated greater staining in the tissue sheath than the ligament or tendon tissue. This was attributed to higher levels of collagen in the tissue, as the collagen may be a barrier between the virus and cells and block transfection. When an excess number of viral particles were used or the injection site was off the intended target, surrounding tissues were transfected. Positive staining of the chicken tendon up to 75 days indicated the adenoviral LacZ transfection was stable and thereby covers a time period sufficient for tendon healing. Extended expression was also attributed to ligament and tendon tissues being less immunoactive. Lastly, the virus dose-transfection rate study indicated the transfection rate is directly linked to the quantity of viral particles injected.
Ex Vivo Gene Therapy Strategies to Intact Ligament and Tendon
To evaluate ex vivo gene transfer, allogenic New Zealand White rabbit patellar tendon fibroblasts were harvested, cultured, transfected using retrovirus, and selected in G-418 prior to injection into the New Zealand White rabbit patellar tendon [Gerich et al. 1997] . In contrast to the in vivo gene transfer approach, the ex vivo gene transfer results indicated transfected cells were not only found in the synovial layer but also throughout the entire tendon aligned parallel to the crimp pattern of the collagen fibers. At six weeks post injection, LacZ expression had significantly decreased and was confined primarily to the tendon; however, at all time points, significantly more transfected cells were found using the ex vivo approach. Transfected cells were also found to have migrated from the injection site to the surrounding tissues. Small areas of fibrotic tissue were observed at two weeks when allogenic transplanted cells were used; however, this was resolved by week six. Controls showed no staining for the marker gene. Using an ex vivo approach, transfected cells were able to integrate in the tendon tissue, while the direct injection of adenovirus particles in vivo limited transfection to the tissue sheath and surface tissue layers. Whether an ex vivo approach is suitable for ligament replacement procedures is unknown. Ligament grafts undergo tissue necrosis and repopulation by synovial fibroblasts. In order for an ex vivo approach to supplement ligament healing, it must be at the initial stages of healing, before tissue necrosis occurs. There is potential for this strategy as gene expression by transfected cells is often greatest immediately following transfection and decreases over time.
Gene Therapy Strategies for Lacerated Tendon Repair
The in vivo and ex vivo gene therapies applied to intact ligament and tendon tissues were expanded by determining the ability of these gene transfer strategies to heal lacerated tendon models [Hildebrand et al. 1999] . Both adenoviral in vivo and retroviral ex vivo gene transfer approaches were explored with gene delivery to the medial collateral and anterior cruciate ligaments of skeletally mature rabbits. In two of the experimental groups, both ends of the medial collateral ligament were ruptured to simulate a traumatic injury common to the knee. This condition was important in determining whether the natural host response to rupture and subsequent healing of the ligament would effect gene expression.
The three experimental groups consisted of (1) retroviral ex vivo gene transfer to the intact MCL and ACL, (2) adenoviral in vivo gene transfer to the ruptured MCL and intact ACL, and (3) adenoviral in vivo gene transfer to intact MCL and ACL. Specifically, the adenoviral gene transfer involved the direct injection of saline containing 10 9 virus particles carrying the β-galactosidase gene (LacZ) into a ruptured or uninjured MCL and the ACL. The retroviral ex vivo technique involved suspending 10 6 transfected allogeneous ligament fibroblasts in saline for injection at the MCL and ACL. The results indicated there was no difference in the length of gene expression to intact and ruptured MCL ligaments following adenoviral in vivo gene transfection. Contrary to the findings at the patellar tendon [Gerich et al. 1997] , the observed duration of LacZ expression at the medial collateral and anterior cruciate ligaments following adenoviral in vivo gene transfer was three weeks in the MCL and six weeks in the ACL. Furthermore, LacZ expression following retroviral ex vivo gene transfer was only observed at day 10 and not the later time points. The short duration of gene expression by the retroviral transfected cells was attributed to either a host immunological response to the allogenic cells or viral antigens. In all instances, the transfected cells were observed incorporated into the crimp pattern of the ligaments.
A more recent model [Lou et al. 2001 ] delivered the therapeutic BMP-12 gene using a direct in vivo approach. In this study, 3 x 10 7 adenoviral particles encoding BMP-12 were injected into the White Leghorn chicken long toe and 3 x 10 7 adenovirus particles encoding LacZ were injected into the contralateral long toe (control), after a complete transverse laceration had been made across the mid-section of each flexor profundus tendon and sutured closed. Whereas other BMPs are characterized by their ability to induce cells to differentiate along an osteoblast pathway, BMP-12 has been shown to induce the formation of ligament and tendon tissue. Results indicated BMP-12 groups had greater callus formation at the injury site than LacZ groups at all time points examined [Lou et al. 2001] . Adhesion formation was observed around all calluses and was greater at the four week time point than the two week time point. Whether the BMP-12 groups had greater adhesion formation than the LacZ groups was not stated and digital range of motion, as a determinate of the extent of adhesion formation, was not evaluated. Mechanical testing in torsion of retrieved long toe specimens transfected with BMP-12 indicated the ultimate force and stiffness was 2-fold greater than controls [Lou et al. 2001] . It is unclear whether BMP-12 gene transfer improved the biomechanical properties of the healing flexor tendons or the increased mechanical properties were due to the increased callus and adhesion formation by these tendons. No histological analysis was reported.
Gene Therapy Strategies to Promote Osseo-Integration of Tendon Grafts
In addition to tissue healing, gene therapy may also be used at the tendon-bone insertion site to promote osseointegration. The ability of adenoviral ex vivo BMP-2 gene transfer to improve osseo-integration of autologous semitendinosus tendons, used to replace the anterior cruciate ligament (ACL) of skeletally mature rabbits, was examined [Martinek et al. 2002] . Autologous semitendinosus tendons were harvested 48 hours prior to ACL reconstruction. Twenty-four hours prior to surgery, the appropriate grafts were transfected with 1.2 x 10 10 particles of adenovirus encoding LacZ, luciferase, or BMP-2. Untreated grafts served as controls. Histological evaluation was completed at 2, 4, 6 and 8 weeks post surgery.
The results indicated LacZ and luciferase gene expression persisted for six weeks post reconstruction. At 8 weeks, untreated control tendons formed a dense connective tissue at the tendon-bone interface, while tendons transfected with the BMP-2 gene possessed a matrix demonstrating a transition from fibrous to cartilaginous tissue with increasing mineralization towards the bone. Mechanical testing, 8 weeks post-operative, indicated the stiffness of the attachment sites was approximately half that of an intact rabbit ACL (29 + 7.1 to 45.3 + 14.1 N/mm) and the ultimate load to failure was under one-third as compared to an intact rabbit ACL (108.8 + 50.8 to 367.2 + 49 N) [Martinek et al. 2002] .
Clinical Trials for Ligament and Tendon Replacement
The aforementioned studies demonstrate the potential of gene therapy in ligament and tendon repair and regeneration. To our knowledge, no gene therapy based clinical trials have been reported for the treatment of defects to the ligament or tendon.
CARTILAGE Introduction
In the United States, over 500,000 cartilage repair procedures are completed each year [Mason, et al. 1998; Laurencin et al. 1999] . The clinical goal in the treatment of cartilage defects is to restore a healthy articular surface; however, this is a challenge due to the tissue's avascularity, which imparts a poor innate healing capacity. Treatment may be further complicated if the defect is a result of joint arthritides. In this instance, the clinician must treat the underlying disease as well as the physical injury. To restore the cartilage surface, penetration of the subchondral bone, osteotomy, joint distraction, tissue grafts, cell transplantations, and artificial matrices are treatment options frequently implemented by the clinician. However, the regenerated cartilage usually possesses inferior mechanical properties and an altered biochemical composition as compared to native cartilage. Where an arthritic condition persists in addition to the cartilage defect, pharmacological agents are available to treat the symptoms of the disease, but are ineffective in preventing disease progression.
A number of cytokines show promise as antiarthritic agents, but their use is hindered by inefficient delivery methods. The proteins cannot be administered orally, thereby requiring either systemic or intraarticular delivery. The short half-life of these molecules; however, requires the administration of high doses or multiple doses, neither of which is ideal for the clinician or patient. As an alternative approach, gene therapy has the potential to circumvent the existing limitations associated with protein delivery by inducing a sustained release of the biologic agent at therapeutic levels. For cartilage tissue, this is achieved by the direct transfer of the gene, which encodes the therapeutic agent, to the cells at the afflicted joint(s) or by implanting cells that have been first genetically modified in vitro. Using these methods, numerous proof of principle experiments have demonstrated the ability to deliver genes in vitro and in vivo to chondrocytes, synoviocytes, chondroprogenitor cells and mesenchymal stem cells with the goal of cartilage regeneration or inhibition of arthritic disease progression. The experience and knowledge gained from these investigations have affirmed the belief that gene therapy is a promising therapeutic strategy for cartilage repair and regeneration following injury or disease and has led to four Phase I clinical trials.
Cartilage Anatomy
Articular cartilage is a thin layer of fibrous connective tissue on the articulating surface of bones in synovial joints. The cartilage allows for movement at articulating surfaces with minimal friction. Mature articular cartilage is approximately 98% extracellular matrix and 2% chondrocytes [Poole et al. 2001] . The chondrocytes are highly metabolically active and are responsible for the synthesis and degradation of the matrix. Mechanical stresses force fluid in and out of the cartilage tissue. This fluid flow provides nutrients to the cells and removes wastes. Collagen types II, IV, IX, X, and XI have been identified in articular cartilage with type II comprising 80 to 90% of the total collagen content . The proteoglycans, which impart cartilage its resilience, elasticity and resistance to mechanical forces (compression), consist primarily of aggrecan with lower levels of decorin, biglycan, lumican and fibromodulin.
Cartilage Pathologies
Injury to cartilage is primarily surface defects, degeneration, or inflammatory degradation. Defects confined to the cartilaginous zone are chondral defects, while defects that penetrate through to the bone are osseochondral defects. The clinical goal in cartilage repair procedures is to restore a healthy articular surface. Various treatment modalities to achieve this goal include penetration of the subchondral bone, osteotomy, joint distraction, periosteum or perichondrium soft tissue grafts, chondrocyte or mesenchymal stem cell transplantations, growth factors and artificial matrices [Buckwalter et al. 1998; Ghivizzani et al. 2000] . These result in marginal repair as often the structure, biochemical composition, and mechanical strength of the repair tissue is often inferior to the native cartilage. Repair efforts that transplant cartilage autografts harvested from the patella, femoral condyle and proximal fibula have been successful; however, the limited quantity of tissue available for harvest restricts this approach to small articular surface defects. One important distinction is that a procedure to address an isolated chondral or osteochondral defect to a single joint of an adolescent or young adult would be inappropriate for the treatment of an older adult with osteoarthritis or rheumatoid arthritis, making cartilage repair a greater challenge for the orthopaedic surgeon than other musculoskeletal tissue injuries.
Over 30 million Americans suffer from arthritides, with rheumatoid arthritis comprising 5 million of the total, and approximately 150,000 new cases of rheumatoid arthritis are diagnosed each year . Rheumatoid arthritis (RA) is a chronic, degenerative joint disease, of unknown etiology, characterized by joint inflammation, synovial hyperplasia, articular cartilage erosion, and abnormal immune response ]. In its most severe form, surgical intervention involving total joint replacement with a prosthetic joint is required. Increased levels of IL-1, tumor necrosis factor-α, IL-6, IL-8, granulocyte-macrophage colony-stimulating factor, and matrix metalloproteinases (MMPs) are found in joints affected by RA Jorgensen et al. 1999] . These proinflammatory cytokines induce the release of MMPs from neutrophils, fibroblasts and chondrocytes [Moreland et al. 1997] . Most research has been directed at inhibiting the actions of IL-1 and TNF-α because in addition to inducing joint inflammation, they also induce chondrocytes to erode the surrounding articular cartilage, prevent the synthesis of new matrix, and have natural antagonists, interleukin-1 receptor antagonist protein (IL1Ra) and tumor necrosis factor receptor fusion protein (TNFR:Fc) Jorgensen et al. 1998; Pelinkovic et al. 2001] . The IL-1Ra protein and TNFR-1Ra proteins compete with IL-1 and TNF-α for cell surface receptors, thereby rendering the IL-1 and TNF biologically inactive. Thus, delivery of IL-1Ra may ameliorate multiple aspects of the disease. Previous RA clinical trials involved the subcutaneous injection of recombinant IL-1Ra protein or intravenous injection of TNFR:Fc protein; however, the rapid loss of the proteins after high-dose injection severely limited the long-term effectiveness of these treatments Moreland et al. 1997] . The in vitro and ex vivo gene delivery of the IL-1Ra cDNA has shown efficacy in a variety of animal models of arthritis and led to a clinical trial that examined the use of gene therapy for RA . The most recent application of anti-TNF gene therapy combated collagen-induced arthritis by the electroporation of a plasmid encoding the TNF receptor linked to a fusion protein to the gastrocnemius muscle in a rodent model ]. Peak serum levels for the TNF receptor:fusion protein complex reached 2.3ng/ml on day five and the beneficial effects lasted for 18 days following a single treatment. In vivo, formation of the TNF:TNF receptor:fusion protein complex neutralized TNF and inhibited its contribution to RA pathogenesis as compared to untreated controls. Cytokine analysis indicated the anti-arthritic effect was achieved by reduced IL-1β and IL-12 levels.
Osteoarthritis is characterized by focal erosions of the articular cartilage surface, depletion of matrix proteoglycans and abnormal chondrocyte metabolism. Changes in chondrocyte metabolism are primarily attributed to the cytokines, IL-1 and TNF. A suitable treatment for osteoarthritis would include the delivery of growth factors and possibly cells to restore the degenerated cartilage and enhance cartilage synthesis in addition to the delivery of proteinase inhibitors to inhibit further cartilage breakdown. An ex-vivo gene therapy approach may be optimal because it would add chondrocytes, chondroprogenitor, or mesenc-hymal stem cells to the area . The delivery of inhibitors of MMPs, which act extracellularly to degrade the cartilage matrix, would cease further matrix breakdown. Precisely which proteinases to be inhibited remain unclear, but the importance of reducing matrix breakdown to preserve the integrity of the articular cartilage has been demonstrated .
Growth Factors and Cytokines for Cartilage Repair and Regeneration
Previous treatments for arthritides focused on the delivery of cytokines to promote matrix synthesis and prevent matrix degradation. The delivery of these molecules; however, as recombinant proteins is not optimal. Recombinant proteins are expensive to produce and their short half life makes it difficult to maintain a high concentration of the biologic agent. When delivered from genetically modified cells, continued factor release has been demonstrated to be more effective than the delivery of recombinant protein. Insulin-like growth factors (IGFs), bone morphogenetic proteins (BMPs), fibroblast growth factors (FGFs), hepatocyte growth factors, and transforming growth factor-β (TGF-β) have been shown to affect chondrocyte metabolism and proliferation [Smith et al. 2000] . Growth factors with selective specificity for cartilage have yet to be identified ].
IGF-1 plays an important role in cartilage homeostasis, has a stimulatory effect on normal chondrocyte matrix synthesis and degradation at concentrations as low as 10 ng/ml, and is upregulated approximately eight weeks following cartilage injury Saxer et al. 2001] . The overproduction of IGF-I has led to neoplastic transformation; therefore, appropriate therapeutic dosages need to be established. The delivery of IGF-1 may be suitable for the treatment of isolated cartilage defects and inappropriate for the treatment of arthritic conditions, as IGF-1 has been demonstrated to be unstimulatory on osteoarthritic chondrocytes. Specifically, the overproduction of IGF binding proteins blocks proper IGF receptor activation .
To investigate cartilage repair using a gene therapy approach, rat perichondral cells, transfected ex vivo via adenovirus to express IGF-I, were implanted in a rodent partial-thickness cartilage defect model ]. Examination of cartilage repair at 8 weeks post-implantation indicated the cells had retained their chondrocyte morphology and had formed a structure that resembled hyaline cartilage and stained positive for collagen type II.
The delivery of the IGF-I gene to rabbit articular chondrocytes resulted in an IGF-I secretion of 80 ng/ml. This level enhanced proteoglycan synthesis, but had no statistically significant effect on type I collagen synthesis. Proteoglycan levels were not only high in the media, but also in the cells, suggesting the newly synthesized proteoglycan was incorporated into a cell-associated matrix [Smith et al. 2000] . The ability to use adenovirus to transfect equine synoviocytes, arranged in monolayer culture or as a tissue explant, with an IGF-1 transgene in vitro assessed transgene expression and the secretion of therapeutic levels by the genetically modified cells. A maximum release of approximately 246 ng/ml (day 4) was followed by decreasing concentrations through day 8. Contrary to observations when using rabbit articular chondrocytes, type I collagen expression by the equine chondrocytes showed a dose-dependent increase, with no significant effect on proteoglycan synthesis . The adenoviral transfection of primary foal chondrocytes with IGF-I gene induced an increase in chondrocyte matrix synthesis. IFG-I was released for 28 days with a peak concentration at day 4 of 66 ng/ml . Furthermore, infected cultures were more resistant to dedifferentiation for the duration of the study. These studies demonstrate the efficacy of IGF-1 gene delivery to enhance cartilage matrix accumulation. Although chondrocytes of different species were tested, the results underline the necessity for a correlation between adenoviral transfection and subsequent dose delivery to be established.
The delivery of a gene to overexpress TGF-β is particularly attractive for osteoarthritic patients because TGF-β has a greater stimulatory effect on osteoarthritic chondrocytes than on normal chondrocytes . TGF-β1 has anti-inflammatory properties and stimulates new matrix synthesis by chondrocytes . However, the direct injection of large doses of TGF-β to the joint can stimulate fibrosis of the synovial lining and osteophyte formation, while systemic injection is immunosuppressive and may lead to fibrosis of tissues, in particular the kidney and liver [Arai et al. 1999; Evans et al. 1999; . Transfection with the TGF-β1 gene was demonstrated to be more effective than IGF-I or BMP-2 genes in stimulating new matrix synthesis from rabbit chondrocytes in vitro ; however, pathological changes have been documented for the intra-articular delivery of adenovirus encoding the TGF-β1 gene ]. These effects were dose dependent. AdTGF-β1 intraarticular injection at the lowest dose, 1 x 10 7 particles, had no adverse effects and no therapeutic effects. The high dose, 1 x 10 9 viral particles, stimulated glycosaminoglycan release, nitric oxide synthesis, fibrogenesis, and muscle edema and physically reduced movement of the injected joint 34 to 50%. Thus, recent evidence strongly suggests a gene therapy approach using TGF-β1 to treat an arthritic condition is inappropriate.
At therapeutic levels, several BMPs will stimulate cell proliferation, stimulate the deposition of extracellular matrix by chondrocytes and inhibit chondrocytes dedifferentiation. Although naturally expressed by chondrocytes, the use of BMPs to enhance cartilage repair must be done with caution, as they are potent stimulators of ossification. BMP-7 has been demonstrated to induce an increase in extracellular matrix synthesis by chondrocytes both in vitro and in vivo using an osteochondral defect model [Hidaka et al. 2001] . It also induces ectopic cartilage and bone formation. Delivery of human BMP-7 via adenovirus increased in vitro matrix specific gene expression by bovine chondrocytes and, when transplanted onto cartilage explants, increased proteoglycan and type II collagen synthesis [Hidaka et al. 2001] . A follow-up study used an equine cartilage defect model to examine the efficacy of allogenic chondrocytes modified ex vivo via adenovirus encoding BMP-7 used for short-and long-term cartilage repair ]. Histological analysis, at 4 weeks post-implantation, indicated defects filled with the BMP-7 expressing cells possessed a smooth repair tissue with the deeper layers well integrated with the subchondral bone. The control defect, which had been filled with allogenic chondrocytes transfected with an insignificant gene, contained fibroblast-like cells in a fibrous matrix. The interface of this matrix with the subchondral bone had gaps. At 8 months post-implantation, very few of the transplanted cells were found at the repair site, and BMP-7 was detected in both experimental and control cartilage defects. Furthermore, gross appearance, MRI, histological, biochemical and biomechanical analysis, at 8 months, indicated no statistically significant difference between the cartilage defects treated with the AdBMP-7 chondrocytes and the control chondrocytes. Thus, BMP-7 producing chondrocytes accelerated the initial stages of cartilage repair, but failed to confer an advantage over the long-term.
Intraarticular injections of recombinant BMP-2 (100 ng) demonstrated a rapid increase in proteoglycan synthesis over the first three days post-injection with a rapid drop-off [van den . Enhanced proteoglycan and, to a lesser extent, collagen synthesis was observed following the infection of rabbit articular chondrocytes with the gene encoding BMP-2 [Smith et al. 2000] . The exposure of these cells to recombinant BMP-2 increased the synthesis of noncollagenous proteins, while BMP-2 produced by the cells post-transfection did not have a statistically significant effect [Smith et al. 2000] . Recombinant BMP-2 is ineffective in counteracting IL-1; however, the delivery of genes encoding BMPs, IGFs and TGF-β stimulated chondrocyte matrix synthesis and inhibited the suppressors of proteoglycan synthesis such as the cytokine IL-1 Smith et al. 2000] . Thus, proteins delivered by genetically modified cells were demonstrated to be more potent stimulators of chondrogenesis than recombinant protein.
Rat perichondral cells transfected ex vivo to express BMP-2 with and without IGF-I were suspended in fibrin glue and implanted in a rodent partial-thickness cartilage defect in the patellar groove of the rat femur ]. The majority of defects in both groups formed a hyaline cartilage-like tissue that stained positive for type II collagen, while untreated fissures and the transplantation of non-transfected cells resulted in an empty defect or a fibrous tissue filling the defect. AdBMP-2 transfected cells did lead to osteophyte formation at the joint margin. This was attributed to the displacement of implanted cells, as excess number of cells was used to fill the defect, and not hypertrophic induction by BMP-2. Tracking of cells transfected with the marker gene LacZ indicated cells were also found in the suprapatellar and lateral recessus and the cruciate ligaments.
The application of genes encoding growth factors in the repair of damaged cartilage continues to be a challenge. There is increasing experimental evidence that growth factor delivery alone is insufficient to treat arthritic conditions. Such an approach would not only address the cartilage defect, but also the underlying disease. This may also restore the imbalance between pro-and anti-inflammatory cytokines or between proteolytic enzymes and their inhibitors. A number of cytokines or cytokine inhibitors, which are able to regulate the inflammatory response, have been identified, and the secretion of matrix metalloproteinases (MMPs) by invading synovial cells results in severe cartilage destruction. To investigate the inhibition of cellular invasion, rheumatoid arthritis (RA) synovial fibroblasts were transfected via adenovirus encoding tissue inhibitors of MMPs (TIMP) [van der Laan et al. 2003 ]. TIMP-1 and TIMP-3 overexpression significantly inhibited the in vitro proliferation of transfected primary RA synovial fibroblasts as compared to AdLacZ transfected control cultures, at all MOI's examined. Furthermore, in vitro studies demonstrated the invasion of a Matrigel ® or Type I collagen matrix by AdTIMP-1 or AdTIMP-3 cells was significantly inhibited as compared to the control, AdLacZ cells. In vivo, the invasiveness of AdTIMP-1 and AdTIMP-3 cells was assessed in a SCID mouse model. Specifically, AdTIMP-1 and AdTIMP-3 transfected RA synovial fibroblasts were individually seeded on Gelfoam sponges and co-implanted with normal human articular cartilage for 60 days. AdTIMP-1 and AdTIMP-3 cells demonstrated reduced invasion as compared to nontransfected and AdLacZ cells. Thus, the modification of synoviocytes with TIMP genes may be one strategy to decrease joint destruction by proteolytic enzymes. Proper application of this method and similar approaches requires an understanding of the role of the factors in cartilage metabolism and the potential side effects of gene transfer on other cells and tissues of the joint.
To date, research in the application of gene therapy for cartilage repair mainly has focused on combating the symptoms, namely inflammation and irritation, of arthritic cartilage. IL-1 and TNF-α are the two principle mediators in rheumatoid arthritis. They drive leukocyte infiltration, synovial hyperplasia and hypercellularity, synovial cell activation, cartilage proteoglycan breakdown, and inhibition of cartilage matrix synthesis [Ghivizzani et al. 1998; Otani et al. 1996] . Biological agents that block the activity of these cytokines include cytokine-specific antibodies, soluble receptor molecules, such as soluble IL-1 receptor protein and soluble TNF-α receptor protein, and receptor antagonists, such as IL-1Ra. In animal studies, delivery of the IL-1Ra has shown promising results. Plasmid DNA containing the cDNA for IL-1Ra was injected in the thigh and calf muscle of a murine collagen-induced arthritis model . Results indicated mice that received the intramuscular injection of IL-1Ra DNA had decreased severity of synovitis and cartilage destruction in the joints. In a rabbit knee model of experimental arthritis, the direct adenoviral delivery of IL1Ra was more effective in inhibiting synovial leukocytosis and cartilage matrix degradation than TNF-α receptor [Ghivizzani et al. 1998 ]. One important finding in this study was that joint leukocytosis, cartilage degradation and synovitis were more reduced following the simultaneous delivery of both inhibitors than the delivery of either one alone [Ghivizzani et al. 1998 ].
Another study examined the double transfection of human RA synovial fibroblasts. The cells were singly or doubly transfected with retroviruses or adenoviruses encoding IL-1Ra and/or vIL-10 [Neumann et al. 2003 ]. Transfected cells were seeded on a sponge with cartilage inserted at the center. This construct was subcutaneously implanted in SCID mice for 2 months. The complementariness of cells expressing the two transgenes was seen as overexpression of vIL-10 inhibited cartilage invasion and IL-1Ra overexpression decreased cartilage degradation. Detection of IL-1Ra and vIL-10 were detected in the serum at 60 days post-implantation indicating adenoviral transfection provided the desired long-term gene expression. Real-time PCR and cDNA analysis indicated the molecular mechanism for the cartilage protective effects by the double transfection involved modulation of the activin pathway. Specifically, activin A subunit, follistatin, and follistatin-related protein were down-regulated and inhibin was upregulated.
IL-10 is multifunctional in combating the symptoms of rheumatoid arthritis. It has been shown to inhibit the proinflammatory cytokines IL-1 and TNF-α at the transcription level ] and IL-6, IL-8, and granulocyte-macrophage colony-stimulating factor [Neumann et al. 2003 ]. IL-10 upregulates soluble TNF-α receptor protein and IL-1Ra, down-regulates MMPs and suppresses the proliferation of some T-cells [Apparailly et al. 1998 ]. Although human IL-10 (hIL-10) may be antiinflammatory and immunosuppressive, in some instances it is immunostimulatory. This may exacerbate the disease symptoms of arthritis and thereby limit the therapeutic use of hIL-10. As an alternative, several investigations have examined the use of a homologue of hIL-10, virus IL-10 (vIL-10), which is encoded by the Epstein-Barr virus. The mature protein of vIL-10 is 84% homologous to hIL-10, has similar anti-inflammatory and immunosuppressive actions to hIL-10, but lacks the immunostimulatory properties. Both systemic administration and intraarticular administration of adenovirus encoding the vIL-10 gene was effective in suppressing the onset of collagen induced arthritis in DBA1 mice .
IL-4 and IL-13, due to shared receptors, overlap on several biological functions. Both inhibit the production of proinflammatory cytokines and upregulate secretion of IL1Ra. IL-4 has been shown to promote tissue repair, by enhancing the formation of type I procollagen in bone from patients with arthritis . The prevention of bone erosion by IL-4 is attributed to the decreased formation of osteoclast cells and down-regulation of IL-17, IL-12, IL-6, and osteoprotegerin in the synovium . Collagen breakdown, which leads to irreversible joint damage, is prevented by the overexpression of IL-4. Although IL-4 treatment protects cartilage destruction, it does not reduce synovial hyperplasia, thought to be due to inadequate apoptosis Relic et al. 2001] .
Cells for Gene Therapy Strategies Directed Towards Cartilage Regeneration
The primary cell target, for in vivo gene transfer with the goal of cartilage regeneration, is synoviocytes. These cells are found throughout the synovial membranes, which line the intraarticular surfaces of the joints. The synovium is an attractive target because it is easily accessible, has a large surface area, and is in direct contact with the joint space. The low antigen presenting capabilities of synoviocytes make them less likely to initiate an immune response following infection Otani et al. 1996; Saxon et al. 2001] . The low proliferative rate of synoviocytes makes the use of retroviral vectors for gene transfer to this cell population only effective in vitro, where culture conditions promote cell proliferation . The use of autologous synoviocytes, transfected ex vivo using retrovirus encoding human IL-1Ra indicated a chondroprotective effect and a mild anti-inflammatory effect. Implantation of the synoviocyte cells in an arthritic rat model indicated cells expressed the cDNA for nine days post implantation, and IL1Ra overexpression suppressed joint inflammation and the erosion of cartilage and subchondral bone [Otani et al. 1996] . The ex vivo genetic modification of rabbit synovial cells to express human IL-1Ra demonstrated that upon in vivo implantation in the rabbit synovium, the transfected synovial cells incorporated into the host tissue and suppressed leukocytosis produced by injection of rhIL-1β [Roessler et al. 1993] . Although vector induced inflammation was not described, sera analysis indicated the development of antibodies directed against adenoviral structural proteins [Roessler et al. 1993] . Contralateral control joints showed no evidence of LacZ expression. Potential disadvantages that may limit the effectiveness of in vivo gene transfer to synoviocytes are the transient expression associated with DNA delivered using adenovirus and the naturally rapid turnover rate of these cells during inflammatory conditions . To date, in vivo gene transfer using animal models has indicated this approach is feasible and secreted transgene products are able to diffuse from the synovium into cartilage and control chondrocyte activity.
In vivo gene delivery to chondrocytes using viral vectors has proved to be technically difficult because the cells are enveloped in extracellular matrix, which prevents viral access to the cells . In vitro, non-viral, lipid-mediated gene transfer to bovine, normal human, and osteoarthritic human articular chondrocytes demonstrated bovine articular chondrocytes had the greatest transfection efficiency at 41% and osteoarthritic human articular chondrocytes the lowest at 7.8% [Mandry et al. 2000] . The in vitro transplantation of genetically modified bovine chondrocytes onto articular cartilage disks demonstrated the ability of these cells to attach, produce extracellular matrix, and continue transgene expression for two weeks, a duration comparable to adenoviral transfection [Madry et al. 2000] . Ex vivo gene transfer using retrovirus delivered the LacZ marker gene to allograft rabbit articular chondrocytes. Upon subsequent re-implantation, the LacZ fell to a low level by 4 weeks post-implantation [Kang et al. 2000] .
The delivery of the TGF-β gene to a human chondrocyte cell line was shown to increase type II collagen synthesis and proteoglycan core protein synthesis while inhibiting the expression of MMP3, a destroyer of proteoglycan [Arai et al. 1999] . The human IL-1 receptor antagonist gene was successfully delivered to human osteoarthritic chondrocytes in vitro. Furthermore, the transplantation of the transfected chondrocytes onto an articular cartilage surface demonstrated the transfected cells adhered, remained viable, and more importantly, the chondrocytes transfected with the IL-1Ra protected the cartilage from IL-1 induced ECM degradation [Baragi et al. 1997] .
As indicated, a wider cell selection, which includes synoviocytes, chondrocytes, chondroprogenitors, and mesenchymal stem cells, exists for ex vivo gene transfer approaches to cartilage repair. As previous experimental work demonstrated the survival and extracellular matrix production by terminally differentiated chondrocytes and undifferentiated mesenchymal stem cells transplanted to articular cartilage defects [Buckwalter et al. 1998 ], these were the first cell types, whose efficiency to uptake and express exogenous DNA, were investigated. Ultimately, cell selection will be largely dependent on the defect to be treated. Chondrocytes may be the preferred cell for the treatment of cartilage surface defects as they naturally synthesize type II collagen and aggrecan. Furthermore, chondrocytes may be harvested as a homogenous cell population and readily transfected. Although ideal from an immunological prospective, the use autologous chondrocytes is limited by the required surgical intervention, the limited quantity of cartilage available for harvest, and the tendency for chondrocytes to dedifferentiate in vitro to a fibroblastlike cell [Fernandes et al. 2000; Yoo et al. 2000] . In the dedifferentiated state, chondrocytes decrease proteoglycan synthesis and are unable to deposit cartilage-specific extracellular matrix [Viengchareun et al. 1997] . Harvesting is further complicated as chondrocytes are enveloped in cartilaginous matrix and cell harvest may be accompanied by tissue damage to a site already difficult to regenerate. Mesenchymal chondroprogenitor cells are cartilage precursor cells that can differentiate into chondrocytes under appropriate conditions and have been found in bone marrow, periosteum, perivascular, synovial and muscle tissues Yoo et al. 2000] . Primary periosteal cells from adult male New Zealand White rabbits were transfected using a retrovirus encoding BMP-7, seeded on polymer grafts, and implanted in 3 mm circular osteochondral defects. Implants were evaluated at 4, 8, and 12 weeks. Results indicated the transgene was expressed for eight weeks and by this time point, the defect, filled with the BMP-7-producing cells, was healed with a hyaline-like tissue. Control defects were poorly healed with fibrocartilage as the dominant tissue .
Bone marrow derived progenitors are another cell source, as mesenchymal stem cells (MSCs) within this cell population have the potential to form a variety of mesenchymal tissues, including cartilage. Bone marrow derived MSCs transfected via lipofection with a sox9 gene, whose expression regulates the gene encoding type II procollagen, demonstrated cartilage formation and differentiation in vitro and in vivo [Tsuchiya et al. 2003 ]. Positive histologic and immunohistochemical results indicated in vitro cultures developed a proteoglycan-rich extracellular matrix and alcian blue staining demonstrated the presence of negatively charged sulfated proteoglycans. Implantation of a diffusion chamber loaded with sox9 transfected MSCs implanted in athymic mice indicated cartilage formation at 8 weeks. Alcian blue and collagen type II was detected, but collagen type X was not. These preliminary findings indicate delivery of the sox9 transgene to MSCs may be a useful treatment for hyaline cartilage damage and warrant further investigation.
Bone marrow progenitor cells have also been genetically modified to secrete TGF-β, which acts through autocrine and paracrine routes, to induce local cellular differentiation along chondrocytic pathways. The multipotentiality of the stem cell may be optimal for full cartilage defects, where ideally some of the cells would be induced to differentiate along a cartilage lineage and others to differentiate along an osteoblast lineage. Mesenchymal stem cells; however, have demonstrated low transfection efficiencies. Optimal viral concentrations for transfection of equine mesenchymal stem cells were shown to be a multiplicity of infection (MOI) of 1000, whereas equine chondrocytes had equivalent transfection at an MOI of 100 .
Gene Delivery Strategies for Cartilage Repair and Regeneration
Recombinant vectors or transfected cells may be delivered in vivo either systemically or locally. A systemic or regional delivery is likely to be used when multiple joints are to be treated, as is the case for patients with severe rheumatoid arthritis. Although the systemic delivery of vectors carrying the cDNA to transcribe the production of anti-inflammatory cytokines has been effective in delaying the onset of arthritis and reducing the severity of symptoms in rabbit models with collagen induced or antigen induced arthritis, the ability of current adenovirus to transfect a wide variety of cell types will limit its clinical applicability. Liver hepatocytes are usually the main target of adenovirus following systemic administration [Jorgensen et al. 1999; Le et al. 1997; Ma et al. 1998 ]. Vector is also present to a lesser extent in the lung and kidney [Jorgensen et al. 1999] .
Local delivery involves a direct intraarticular injection of the genetically modified vectors or transfected cells. Following local vector delivery, adenovirus fails to target the heart, liver, lung, spleen, and kidney tissues [Ghivizzani et al. 1998 ]. The direct intraarticular injection of adenovirus encoding vIL-10 or IL-10 into the knees of DBA1 mice induced a humoral and cellular immune response Ma et al. 1998 ]. The authors attributed this primarily to the expression of viral proteins by the transfected cells. Other investigations have found a similar immunostimulatory response following the injection of adenoviral particles into joint capsules ]. This condition is possibly dose dependent as no inflammation was noted at lower doses of adenovirus . Other investigators using a similar model reported a limited, transient effect from systemic delivery and significant ablation of CIA with intraarticular injection and no side effects . The direct intraarticular injection of adenoviral doses less than 7 x 10 9 particles into the knee joints of rabbits with antigen induced arthritis generated a mild inflammatory response . The differ-ences seen may be due to inherent differences in the animal models, titers of virus, site of injection, purity of virus preparation, and virus storage buffer conditions . The successful synoviocytes transfection with cDNA encoding for cytokines with immunosuppressive properties, such as vIL-10, was ineffective in the prevention of viral induced synovitis. In a similar study, adenoviral injections at a lower dose, above 1 x 10 9 PFU, inflamed naïve rabbit joints and exacerbated the pathology in knees with antigen induced arthritis and truncated transgene expression within 3 to 7 days [Ghivizzani et al. 1998 ]. Lower adenoviral doses of 7 x 10 7 PFU induced no irritation and maintained detectable levels of gene expression for up to 14 days. New adenoviral vectors must be developed that allow for the administration of fewer viral particles or reduce the antigenicity of cells transfected using adenovirus [Ghivizzani et al. 1998 ].
The intraarticular injection of adenoviral constructs carrying the cDNA encoding equine IL-1Ra revealed a dose dependency in synovial fluid aspirates, with the maximal duration for 28 days occurred with 10 and 20 x 10 10 particles per joint. Interestingly, this concentration was associated with the shortest transgene expression period. A concentration of 50 x 10 10 particles per joint produced acute synovial fluid leukocytosis, which was not observed at the lower doses [Frisbie et al. 2002] .
Although most experimental models look at the use of gene therapy as a treatment of arthritides, there is also the potential for gene therapy to supplement current practices. Total joint arthroplasty is a common procedure for severely arthritic joints. The most common complication is prosthetic loosening due to adverse tissue response from wear debris particles from the artificial joint. Recently, the retroviral delivery of human IL-1Ra, human TNF-soluble receptor protein, and vIL-10 were effective in decreasing the inflammatory response and macrophage influx in murine air pouches stimulated by ultra high molecular weight polyethylene (UHMWPE) and poly(methyl methacrylate) (PMMA) cement particles [Sud et al. 2001; Yang et al. 2002,] . The delivery of genes encoding anti-inflammatory cytokines combines gene therapy techniques with current surgical procedures to reduce post-surgical complication associated with total joint arthroplasty.
Non-viral gene delivery systems avoid the risk of insertational mutagenesis and immunogenicity associated with retroviral vectors and do not limit the size of the DNA that can be delivered. In lipid-mediated gene transfer, a dosedependent increase in gene transfer was observed by increasing the DNA content up to 1 µg. Greater quantities of DNA reduced the transfection efficiency [Mandry et al. 2000] . Optimal transfection varies by the non-viral transfection method and cell type used.
The canine IL-1Ra gene has also been delivered to rabbit synoviocytes and chondrocytes using the in vivo gene transfer through the direct delivery of a lipoplex (plasmid complexed to a lipid) in a rabbit model of osteoarthritis. Although staining for IL-1Ra was absent in the low dose of 500µg, the high dose 1000µg did stain [Fernandes et al. 2000] .
The hemaglutinating virus of Japan (HVJ; Sendai virus)-liposome suspension containing SV40T antigen was injected intra-articularly into the knee joints of Lewis rats [Tomita et al. 1997] . The complex was 150-200 nm in size and the SVT gene was found to transduce chondrocytes residing in the superficial and middle cartilage layers. About 30% of the cells were transfected. More importantly, the efficiency of transfection was stable for the 21 days examined. Additionally, no pathological changes were observed in tissues. Examination of distant organs, including the heart, lung, liver, spleen and kidney were all SVT free [Tomita et al. 1997] .
While the majority of gene transfer strategies have focused on the delivery of growth factors, cytokines, and cytokine receptors, more recently, progress in interfering with signaling pathways involved in activation of the apoptosis of synovial cells induces a genetically induced synovitis [Pap et al. 2000; Yao et al. 2003 ]. This may be accomplished by the delivery of the thymidine kinase gene followed by the intravenous administration of ganciclovir. This approach is designed to parallel the results observed after a surgical synovectomy without the undesirable side effects, including applicability only to large joints, high cost, difficulty, ligamentous instability and lost range of motion [Sant et al. 1998 ]. The rational behind this approach is the association of inflammatory arthritides with the proliferation of synovial fibroblasts. This uncontrolled growth also participates in the cellular processes that lead to the erosion of cartilage and bone as well as chronic immune activation. Roessler and colleagues incorporated the herpes simplex virus-thymidine kinase gene into a DNA plasmid. The modified DNA was then injected intra-articularly to rabbits with antigen-induced arthritis. At 21 days post-treatment, cytolysis was observed for cells of the synovial lining. No evidence of cytolytic damage was observed in the underlying articular cartilage or bone, and thymidine kinase gene expression was absent from distant organs.
Another genetic approach to treat synovitis involves the use of adenovirus encoding the TNF-related apoptosis inducing ligand (TRAIL) [Yao et al. 2003 ]. TRAIL has been reported to selectively induce apoptosis in transformed cells, with a minimal effect on the viability of normal cells. In vitro studies demonstrated transfection of human RA synovial cells with the TRAIL gene resulted in significant apoptosis for 60% of the cell cultures. In vivo, the intraarticular injection of 5 x 10 5 rabbit synovial cells genetically modified to express IL-1β induced an arthritic condition in the knee joints of New Zealand White rabbits. Four days post-arthritic induction, AdTRAIL particles were injected into the knee joints. Tissues of the control joints, that received an AdLacZ injection, remained thickened and highly cellular, while AdTRAIL injected joints had extensive acellular areas in the synovial lining and induction of new matrix synthesis. The in vivo therapeutic effects imparted by AdTRAIL injection warrant further investigation into this treatment approach for RA. Whether the AdTRAIL treatment would be as effective if genetically modified cells had not been used to induce the synovitis was unaddressed.
Dose Dependency Detected with Cartilage Gene Therapies
Treatment of the arthritic condition in animal models using adenoviral in vivo gene transfer has been shown to be dose dependent. The expression of IL-4 following intraarticular delivery via adenovirus in the mouse knee joint demonstrated dose dependency as a minimum of 1x10 7 PFU were needed to suppressed type I collagen breakdown in DBA1 mice with collagen induced arthritis (CIA). Although inflammation persisted, bone erosion and joint destruction (collagen breakdown) in the knees of mice was prevented .
The single intravenous administration of adenovirus encoding human p55 TNFR-IgG Fusion protein in established CIA was effective in ameliorating CIA for 10 days. At later time points, a greater inflammatory response was observed despite the continual presence of the bioactive TNFR fusion protein [Quattrocchi et al. 1999] .
Systemic administration of 10 10 PFU of adenovirus encoding vIL-10 (Ad-vIL-10) was effective in decreasing the severity of cartilage induced arthritis in the DBA1 mouse model. This high dose not only demonstrated less severe synovial hyperplasia, cartilage destruction and bone erosion [Apparailly et al. 1998; Ma et al. 1998 ], but also delayed the onset of the arthritis for 15 days [Apparailly et al. 1998 ]. Higher doses induced morbidity, while the administration of lower doses led to undetectable levels of IL-10 in the serum [Ma et al. 1998 ]. Dose dependency is also observed with intraarticular injection of AdIL-10 into CIA murine model [Lubberts C 1998; . The local administration of 1 x 10 8 PFU of AdIL-10 resulted in detectable levels of IL-10 in the circulation at day 1. The intraarticular injection of lower doses did not result in detectable systemic IL-10 levels .
Treatment of the arthritic condition with adenovirus encoding vIL-10 or IL-10 in a CIA mouse model was ineffective in the case of established disease Ma et al. 1998 ]. These results correspond to the dominant role of IL-1 in established CIA. The delivery of Ad-vIL-10 to established Ag-induced arthritis in rabbits had a significant effect in abating the arthritic condition . The authors attribute this discrepancy to inherent differences in the models of disease. The delivery of adenovirus encoding TNF-α receptor protein in the same model significantly suppressed CIA prior to and following arthritis onset [Le et al. 1997] .
Therapeutic Effects by Transfected Cells on Distal Joints
Interestingly, following the injection of adenoviral particles encoding vIL-10 into mouse knee joints the onset of CIA in the paws of the DBA1 mice was delayed [Ma et al. 1998 ]. This global effect was also demonstrated as the injection of adenovirus encoding vIL-10 into a single joint suppressed CIA in the other non-injected paws up to 10 weeks , in the contralateral knee of rabbits with antigen induced arthritis , and in the contralateral paws of delayed-type hypersensitivity mouse model [Whalen et al. 2001] . At that time, a definitive statement as to whether these global effects are due to the leakage of virus into systemic circulation or the migration of locally transfected leukocytes to distant joints through either systemic circulation or the lymphatic system was unknown. The possibility of therapeutic effects on distal joints being due to the secretion of protein into the bloodstream was believed improbable due to negligible amounts of protein detected in collected serum and the short half-life of the proteins [Whalen et al. 2001] . At day 3 and day 7 following the intraarticular injection of adenovirus particles encoding soluble TNF-α receptor protein, protein levels of lavage fluids from the injected joint were 20 ng/ml, whereas protein levels detected in the sera or lavage fluid from the contralateral joint were not more than 1 ng/ml [Ghivizzani et al. 1998 ]. Data from the investigation of rabbits indicated it was the trafficking of genetically modified leukocytes that produced the contralateral effect [Ghivizzani et al. 1998 ]. The injection of adenoviral vectors (2 x 10 9 ) encoding the luciferase gene into a single knee joint of a rabbit with bilateral antigen induced arthritis led to luciferase expression in the injected knee, the draining lymph node, and the contralateral knee joint [Ghivizzani et al. 1998 ]. The adenoviral delivery of the vIL-10 gene into a delayed-type hypersensitivity murine model suppressed inflammatory arthritis in the injected and contralateral paws. The data suggest transfected antigen-presenting dendritic and macrophage cells migrated to distant joints and lymph nodes where they suppress cell mediated immune response and lymphocyte proliferation, respectively. These findings, however, fail to explain the incidence of global immunosuppression. The inhibition of arthritis in distal joints was more effective following local adenoviral delivery than systemic delivery [Whalen et al. 2001] . Results from cell trafficking studies seemed to indicate; however, a population of leukocytes exists which migrates from the treated joint to the contralateral joints . It is believed that these cells are either macrophages or immature dendritic cells. Furthermore, although detected, the level of gene products in the contralateral joints was too low to confer a therapeutic effect.
To develop a greater understanding of the underlying immunologic mechanism of the contralateral effect, in vivo gene therapy to suppress induced arthritis in a dual-antigen model was used ]. Rabbits were immunized against two different antigens, ovalbumin and keyhole limpet hemocyanin, injected contralateral to each other in the rear knee joints. Results, following the intraarticular injection of adenovirus encoding vIL-10, indicated reduced leukocyte infiltration into the joint space and a reduced degree of synovitis in treated joints. While AdvIL-10 was able to confer the contralateral effect in monoantigenic induced arthritis models, it failed to do so in the dual antigen induced arthritis model. This suggests that the distant antiarthritic effects observed was due to an antigen-specific down-regulation of inflammation and not attributable to a global immunosuppression resulting from circulating levels of transgene product.
Cell trafficking is believed to depend on the amount of inflammation, the number of transfected cells within the injected joint, and the amount of inflammation in the contralateral joint . It has been hypothesized that following the intra-articular injection of viral vectors, antigen-presenting cells present at the injection site become genetically modified. These cells disseminate the therapeutic effect by trafficking to spleen, lymph nodes, and sites of inflammation . A recent study; however, challenged this hypothesis by the intraarticular delivery of autologous fibroblasts modified ex vivo prior to implantation ]. The therapeutic response observed in treated joints and distal untreated joints strongly suggested direct in vivo genetic modification of resident cells within the joint was not a requirement for the contralateral effect.
The intraarticular delivery of soluble IL-1 receptor fusion protein and soluble TNF-α receptor fusion protein to one knee of rabbits with antigen induced arthritis reduced cartilage matrix degradation and white blood cell infiltration more than the delivery of either receptor alone in the injected and contralateral knees [Ghivizzani et al. 1998 ]. In addition, there was a reduction in synovitis. A follow-up study investigated the intra-articular implantation of autologous fibroblasts genetically modified ex vivo to overexpress the IL-1 receptor antagonist protein and/or soluble TNF-α receptor . Results indicated the modified cells conferred an anti-inflammatory and chondroprotective effect on the injected and non-injected contralateral joints, while the delivery of cells expressing both transgenes exhibited a synergistic effect in reduction of the arthritic condition. The results from these studies suggest targeting multiple arthritic inducing agents may be more effective than blocking individual molecules. This is in agreement with the etiology of rheumatoid arthritis as being an imbalance of multiple cytokines [Ghivizzani et al. 1998 ].
Using a murine model, adenovirus encoding the murine IL-18 binding protein isoform c gene (AdIL-18BPc), which binds to and neutralizes the proinflammatory cytokine IL-18, was injected at the knee joint two days prior to induced arthritis [Smeets et al. 2003 ]. Treated joints demonstrated reduced inflammation and reduced destruction of bone and cartilage. Furthermore, these effects decreased the severity of CIA in the distal paws. Whether these results were due to an inhibition of cytokine spreading or the leakage of AdIL18BPc or IL-18BPc to the distal paw is unknown. Although AdIL-18BPc treatment reduced the symptoms of CIA as compared to the control treatment, IL-18BPc was not able to completely arrest the progression of the disease in some animals.
A short term (5 day) study demonstrated the production of human IL-1Ra was able to prevent the onset of collagen induced arthritis at the injected knee and draining paw; the contralateral knee and remote paws developed full-blown arthritis [Bakker et al. 1997] . The cell line used is compatible with DBA/1 mice, but it is unknown whether longer time points would terminate gene expression due to graft rejection.
There has also been evidence that localized delivery can have therapeutic effects on distal joints. Following intraarticular administration, leakage of the virus and/or gene product was detectable in the circulation, adjacent lymph nodes, and distal joints [Ghivizzani et al. 1998; Le et al. 1997; Ma et al. 1998 ]. Whether the cells travel via the circulatory or lymphatic system is unknown. The intraarticular delivery of adenovirus encoding IL-10 into the mouse knee joint during the early onset of CIA suppressed arthritis in the ipsilateral paw and at higher doses delayed arthritis onset in the contralateral paw .
Transfected Xenogenic Cells for Cartilage Repair
Strategies have also focused on the engraftment of Chinese hamster ovary (CHO) cells, transfected with a plasmid construct containing the cDNA encoding IL-13, IL-4, or IL-10 injected into the dorsal surface of DBA1 mice. This resulted in a milder form or completely suppressed collagen induced arthritis, respectively [Bessis et al. 1999] . Although cell trafficking and viability following in vivo engraftment was not monitored, the authors believe the xenogenic cells were likely rejected. Their presence; however, was long enough to alter the severity of the collagen induced arthritis [Bessis et al. 1999] . Similar findings were reported for the intraarticular injection of adenovirus encoding viral IL-10 (Ad-vIL-10). Although AdvIL-10 was only detected for three weeks, the protective effects continued throughout the ten weeks of the study, indicating the continued expression of the viral protein unnecessary [Whalen et al. 2001] . The delivery of cytokines with immunosuppressive properties, such as vIL-10, did not increase the duration of transgene expression.
Microencapsulation of the transfected cells in hollow fibers of the copolymer AN-69 allowed for the diffusion of the therapeutic agent in to the host while protecting the cells from immune attack [Bessis et al. 1999] . Both CHO/IL-4 and CHO/IL-13 encapsulated cells delayed the onset and severity of CIA in DBA1 mice. As cell trafficking is prevented, if necessary, a second surgical procedure can easily retrieve the implant and all the transfected cells from the intraperitoneal cavity. This is not possible with other ex vivo and in vivo gene transfer strategies.
To assess the effects of vIL-10 delivered via gene therapy on human rheumatoid synovial tissue, the human arthritic tissue was engrafted subcutaneously on SCID mice and systemically injected with 10 9 PFU of Ad-vIL-10. Three weeks post vector injection, histological analysis of the graft indicated the systemic vIL-10 gene transfer prevented cartilage invasion by synovial tissue [Jorgensen et al. 1999] . A sustained level of vIL-10 protein was detected in the mouse sera for 40 days and in the synovial tissue 21 days after adenoviral injection. The xenograft of human tissue made this a more clinically relevant model and led to a clinical trial to treat rheumatoid arthritis with recombinant human IL-10.
Cartilage Tissue Engineering and Gene Therapy
Numerous biologic and non-biologic materials have been used to construct tissue engineered scaffolds for cartilage repair. These include cartilage and bone matrices, collagens, fibrin, carbon fiber, hydroxylapatite, polytetrafluoroethylene, polyester, and synthetic polymers. These approaches have contributed to the restoration of articular surfaces, but a consistently reliable means of cartilage repair does not exist. The limited success with cell-based tissue engineering strategies to regenerate cartilage makes adding a gene therapy approach attractive. Furthermore, the extensive death of chondrocytes in osteoarthritis and rheumatoid arthritis may necessitate the replacement of the cell population as well as void filler.
In one study, an osteochondral defect (3 mm diameter x 3 mm depth) was created in the medial femoral condyle of New Zealand White rabbits and filled with an alginate bead, which contained transfected primary rabbit bone marrow stromal cells expressing enhanced green fluorescent protein (EGFP) [Milbrandt et al. 2003 ]. Results indicated, by four weeks post-implantation, the number of cells expressing EGFP was decreased and mostly located at the surface.
Furthermore, the cellular morphology of the transfected cells had changed from a rounded to elongated shape. The authors did not speculate whether the altered morphology was a result of the transfection or due to a condition encountered in the in vivo environment. The disappearance of the cells by six weeks post-implantation was believed to represent the lifespan of the cells and not a host immune response, as no signs of inflammation were present [Milbrandt et al. 2003 ].
As a more durable scaffolding material than gels, a biodegradable type I collagen sponge was used to retain transfected cells in surgically created articular defects. Allogenic chondrocytes were transfected ex vivo using adenovirus encoding the LacZ gene, seeded onto a type I collagen sponge, and implanted into shallow and deep articular cartilage defects using New Zealand White rabbits [Baragi et al. 1997] . The scaffold served as a carrier for the genetically modified cells and retained the cells at the defect site. Although LacZ expression was evident at day 10 postimplantation, extensive cell loss (~90%) over the first 24 hours was a major concern [Baragi et al. 1997] . This cell death was too rapid to be attributed to a humoral immune response, and the authors hypothesized that mechanical forces effected transplanted cell survival.
An ex vivo gene transfer approach used retrovirus to deliver the cDNA to periosteal-derived rabbit mesenchymal stem cells [Mason et al. 1998 ]. The BMP-7 transfected cells were subsequently seeded onto polyglycolic acid grafts, 4 mm diameter x 2 mm thickness, 4 x 10 6 cells/graft and cultured for 1 week in vitro prior to implantation. The BMP-7 producing cells/PGA scaffold was subsequently implanted into 2 mm wide x 3 mm deep osteochondral defect in the femoropatellar groove. Preliminary studies demonstrated the delivery of a LacZ marker gene was expressed for 2 months for transfected cells placed on the PGA scaffold and implanted into the femoropatellar groove osteochondral defect.
Allograft periosteal stem cells transfected with a BMP-7 or sonic hedgehog (shh) gene were seeded onto bioresorbable, polyglycolic acid foam matrices and implanted into a full-thickness osteochondral defect [Grande et al. 2003 ]. Scaffolds seeded with BMP-7 producing cells had a significantly greater amount of hyaline cartilage formation and accelerated repair of the subchondral bone as compared to the empty defect at 6 weeks post-implantation. Shh producing cells seeded on the PGA scaffold resulted in accelerated, high-quality hyaline cartilage formation; however, bone formation in the subchondral compartment was delayed and less in quantity. Matrices seeded with BMP-7 producing cells had a significantly greater amount of hyaline cartilage formation and accelerated repair of the subchondral bone as compared to the empty defect at 6 weeks post-implantation. These scaffolds also repaired the osseous portion of the defect most rapid. As some of the control defects, at 26 weeks post-operative, demonstrated a fully restored articular surface, the authors concluded technologies that use scaffolds alone or in combination with transfected cells may prove useful for cartilage repair.
Clinical Trials
Evans and colleges ] undertook the first clinical trials using gene therapy as a treatment for rheumatoid arthritis. This ex vivo gene transfer approach harvested autologous synovial fibroblasts during total joint arthroplasty or synovectomy. Harvested cells were culture expanded and transfected with the MFG vector, a replication deficient retrovirus derived from Moloney murine leukemia virus, which contained the cDNA encoding for human IL1Ra. Non-transfected cells served as the control. The transfected synoviocytes were injected at the metacarpophalangeal joints of the patients one week before the joints were removed during total joint replacement surgery. The goals of this clinical trial were to determine whether it is possible to deliver IL-1Ra from the transplanted, autologous, genetically modified synoviocytes in a manner safe and well accepted by the patients . Analysis of the retrieved tissues indicated high levels of IL-1Ra on the synovial surfaces of the joints injected with transfected synoviocytes .
A similar study is underway in Dusseldorf, Germany; however, in this clinical trial, the transfected, autologous synoviocytes are implanted for one month prior to joint removal . To date, three subjects have undergone the treatment ]. Two more clinical trials, one in the United States and one in the Netherlands, have been approved to induce a genetic synovectomy. In these clinical trials, a gene encoding herpes thymidine kinase will be transferred to the joints of patients with rheumatoid arthritis and gancyclovir will be administered . One subject has undergone the procedure ].
CHALLENGES AND FUTURE DIRECTIONS
Within the past few years, several advances have been made in the use of gene therapeutics to treat musculoskeletal disorders. These accomplishments have successfully led to the first clinical trials using gene therapy to treat rheumatoid arthritis. Before clinical trials using gene therapy to treat osseous or ligament defects may be initiated, the physician must be provided with a more thorough understanding of gene therapy as a treatment option. Researchers must be able to show a greater comprehension and control over how to implement a gene therapy technique to achieve a desired response with minimal to no adverse affects. The contralateral effect is one example. Investigators have supporting evidence that this phenomenon is not attributable to circulating transgene product. Several investigations monitored cell trafficking and indicate in vivo genetically modified leukocytes at the injected joint migrate to the contralateral joints to confer a therapeutic effect. However, most recently, this was challenged as the intra-articular injection of cells genetically modified ex vivo bestowed a contralateral effect. Elucidating the mechanism behind the contralateral effect is important as it may guide future gene therapy treatment procedures and dosages administered.
Other issues concern the resolution between in vitro and in vivo results. Although one may be able to map protein secretion in vitro, the in vivo environment and immune system may cause a different pattern of protein expression. Depending on the target protein and in vitro versus in vivo variability the expected therapeutic effect may not be observed. This may be largely attributable to the fact that in vitro experimental results are obtained under highly controlled conditions. In vivo, many reactions and signaling systems are active concurrently. It is highly difficult to develop a complete understanding of the effect these processes have on the therapeutic results.
Another aspect that must be investigated in determining an appropriate clinical approach for gene therapy in musculoskeletal healing is the varied genetic backgrounds of the animals models used. Inconsistencies exist when comparisons between the healing responses observed by immune compromised animals are compared to immune competent animals. Different animal strains will possess differences in genetic expression that may influence the efficacy of vector transfection, transgene expression, host immunological response, transgene bioactivity, and ultimately the observed healing response. An examination of six immunocompetent rat strains, including Wistar, LongEvans, Sprague-Dawley, ACI, PVG, and Fischer344 rats, indicated the different strains had different T-cell levels and different potentials to produce adenoviral neutralizing antibodies after adenoviral injection ]. Furthermore, the expression of BMP target genes delivered via adenoviral vector to primary muscle cell cultures in vitro were significantly different between some of the rat strains and thus altered their potential for ectopic bone formation. Although there are many advances to be attained before the customary clinical use of orthopaedic applications of gene therapy, the first human clinical trial using a gene therapy approach to treat rheumatoid arthritis was inspirational and exemplifies of the potential of gene therapy to treat other musculoskeletal disorders.
